Document:

EX-4.13

 Exhibit 4.13 
  

					
	Confidential	  		  	Execution Copy

 DATED 13 December 2010 

IMMUTEP S.A. 
 - and - 

GLAXO GROUP LIMITED 
  

 

 

LICENCE & RESEARCH 

COLLABORATION AGREEMENT 
  

 

 
  

					
	                        	 	Certain information marked [***] has been excluded from the exhibit because it is not material and would likely cause competitive
harm to the company if publicly disclosed.	 	                        

  
 1 

					
	Confidential	  		  	Execution Copy

  

 THIS AGREEMENT dated the         day of December 2010 (the
“Effective Date”) 
 BETWEEN: 
  

	 	(1)	 IMMUTEP S.A., a company organized under the laws of France with its registered offices at Parc Club
Orsay, 2, rue Jean Rostand, 91893 ORSAY, France (“Immutep”); and 

  

	 	(2)	 GLAXO GROUP LIMITED, a company existing under the laws of England and Wales, having its registered
office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”). 

 BACKGROUND

 Immutep is a biotechnology company, which has developed expertise in relation to the Monoclonal Antibody with
LAG-3 positive (LAG-3+) cell depleting activity (as defined below). 
 GSK
possesses expertise in the pharmaceutical research, development, manufacturing and commercialization of human pharmaceuticals, and GSK is interested in researching and developing the Monoclonal Antibody as a drug product; 

GSK desires to obtain an exclusive licence to the Monoclonal Antibody and other related technologies and know-how
owned or controlled by Immutep, and Immutep is willing to grant such a licence on the terms set out in this Agreement; and 
 In addition to the above
licence, Immutep and GSK desire to engage in a collaborative effort pursuant to which Immutep shall carry out certain research with regard to the Monoclonal Antibody in the Field. 

NOW, THEREFORE, in consideration of the mutual covenants set out below in this Agreement, the receipt and sufficiency of which are hereby acknowledged,
the Parties hereby agree as follows: 
 1 DEFINITIONS 

As used in this Agreement and the Schedules to this Agreement the following capitalized terms, whether used in the singular or plural, shall have the meanings
set out below: 
  

	 	1.1	 “Acceptance” means, with respect to a Marketing Authorisation Application filed for a
Licensed Product, (a) in the United States, the receipt by GSK of written notice from the FDA in accordance with 21 CFR 314.101(a)(2) that such Marketing Authorisation Application is officially “filed”, (b) in the European Union,
receipt by GSK of written notice of acceptance by the EMA of a Marketing Authorisation Application for filing under the centralized European procedure; provided, that if the centralized filing procedure is not used, then Acceptance shall be
determined upon the acceptance of such Marketing Authorisation Application by a Regulatory Authority in the first of the following countries: UK, France, Germany, Italy or Spain. 

 

	 	1.2	 “Affiliate” means any partnership, corporation or other entity which is directly or indirectly
Controlling, Controlled by or under common Control with or of a Party for so long as such Control exists. 

  

	 	1.3	 “Alliance Manager” has the meaning assigned to such term in Clause 6.11.

  
 2 

					
	Confidential	  		  	Execution Copy

  

	 	1.4	 “Applicable Laws” means the applicable provisions of any and all national, supranational,
regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidances, ordinances, judgments, decrees, directives, injunctions, orders, permits (including Marketing Approvals) of or from any court, arbitrator,
mediator, Regulatory Authority or governmental agency or authority having jurisdiction over or related to the subject item. 

  

	 	1.5	 “Business Day” means any day other than a Saturday or Sunday on which banking institutions in
London, England are open for business. 

  

	 	1.6	 “Calendar Quarter” means the period beginning on the Effective Date and ending on the
last day of the calendar quarter in which the Effective Date falls, and thereafter, each successive period of three (3) consecutive calendar months ending on March 31, June 30, September 30 or December 31. 

 

	 	1.7	 “Calendar Year” means the period beginning on the Effective Date (or, with respect to the year
in which a Licensed Product is first launched, the date of the First Commercial Sale of such Licensed Product in the first country in which a First Commercial Sale occurs) and ending on December 31st of the calendar year in which the Effective Date
(or such First Commercial Sale) falls, and thereafter, each successive period of twelve (12) consecutive calendar months commencing on January 1 and ending on December 31. 

 

	 	1.8	 “Change of Control” shall mean either: (a) a sale of all or substantially all of the
assets of Immutep in one or a series of integrated transactions not in the ordinary course of business to a Third Party; or (b) a transaction or series of transactions that results in the holders of outstanding voting securities of Immutep
immediately prior to such transaction not beneficially owning, directly or indirectly, at least fifty percent (50%) of the combined outstanding voting power of the acquiring entity (or of Immutep if it is the surviving entity in any merger or
consolidation), or its direct or indirect parent entity, immediately after such transaction or series of related transactions. 

  

	 	1.9	 “Collaboration IP” means collectively, the Immutep
Non-Licensed Arising IP, Immutep Licensed Arising IP, GSK Non-Licensed Arising IP, GSK Licensed Arising IP, Joint Non-Licensed
Arising IP and the Joint Licensed Arising IP. 

  

	 	1.10	 “Collaboration Patents” means collectively, the Immutep Licensed Arising Patents, the Immutep Non-Licensed Arising Patents, the GSK Licensed Arising Patents, the GSK Non-Licensed Arising Patents, the Joint Licensed Arising Patents and the Joint Non-Licensed Arising Patents. 

  

	 	1.11	 “Commercially Reasonable Endeavours” means commercially reasonably endeavours in the
conduct of each Party’s activities, as provided under the Agreement, in the research, development and commercialisation of the Licensed Product, such endeavours to be consistent with the endeavours and resources normally used by the respective
Party in the exercise of its reasonable business discretion relating to a pharmaceutical product owned by it or to which it has exclusive rights, with similar product characteristics, which is of similar market potential at a similar stage in its
development or product life, taking into account issues of scientific risk, patent coverage, safety and efficacy, product profile, the competitiveness of the marketplace, the proprietary position of the compound or product, the regulatory structure
involved, the profitability of the applicable products (including pricing and reimbursement status likely to be achieved), and other relevant factors, including technical, legal, scientific and/or medical factors. 

 

	 	1.12	 “Confidential Information” has the meaning assigned to such term in Clause 12.1.

  

	 	1.13	 “Control,” “Controls,” “Controlled” or
“Controlling” means; 

  

	 	1.13.1	 in respect of any partnership, corporation or other entity, the direct or indirect ownership of at least fifty
percent (50%) of the outstanding shares or other voting rights of the subject entity having the power to vote on or direct the affairs of the entity, (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a
particular jurisdiction). Any other relationship which in fact results in actual control over the management, business and affairs of an entity shall also be deemed to constitute Control; and 

  
 3 

					
	Confidential	  		  	Execution Copy

  

	 	1.13.2	 in respect of any Patent, Know-How or other Intellectual Property
whether owned by or licensed to an entity, the possession of the legal right and ability to grant the respective licenses or sublicenses as provided herein without violating the terms of any agreement or other arrangement with any Third Party;

  

	 	 	 and the expressions Controlling and Controlled by shall be interpreted accordingly. 

 

	 	1.14	 “Disclosing Party” has the meaning assigned to such term in Clause 12.1.

  

	 	1.15	 “EMA” means the European Medicines Agency and any successor entity thereto.

  

	 	1.16	 “Executive Officer” has the meaning assigned to such term in Clause 6.7.

  

	 	1.17	 “FDA” means the U.S. Food and Drug Administration and any successor entity thereto.

  

	 	1.18	 “Field” means [***]. 

 

	 	1.19	 “First Commercial Sale” means, with respect to the Licensed Product, the first lawful
sale, transfer or disposition for value of such Licensed Product in the Territory having received Acceptance; provided, that, the following shall not constitute a First Commercial Sale: (a) any sale to an Affiliate or Sub-licensee unless the Affiliate or Sub-licensee is the last entity in the distribution chain of the Licensed Product and is purchasing it for its own commercial use,
(b) any use of such Licensed Product in clinical studies or other research or development activities, or disposal or transfer of such Licensed Product for a bona fide charitable purpose, (c) compassionate use, (d) so called
“treatment IND sales” and “named patient sales”, (e) registration samples, and the like. 

  

	 	1.20	 “Good Data Management Practices” has the meaning assigned to such term in Clause 4.3.3.

  

	 	1.21	 “GSK Arising IP” means GSK Non-Licensed Arising
IP and the GSK Licensed Arising IP. 

  

	 	1.22	 “GSK Arising Patents” means any and all Patents within the GSK Licensed Arising IP and the GSK
Non-Licensed Arising IP. 

  

	 	1.23	 “GSK Background IP” means any and all Intellectual Property which exists as of the
Effective Date or is generated outside of the Agreement, which in either case is Controlled by GSK or its Affiliates. 

  

	 	1.24	 “GSK Licensed Arising IP” has the meaning assigned to such term in Clause 9.3.1(d).

  

	 	1.25	 “GSK Non-Licensed Arising IP” means any
Intellectual Property which is invented solely by GSK during the Research Programme, and which has not arisen directly from the use of the Merck-Serono IP. 

  

	 	1.26	 “GSK Programme IP” mean any Intellectual Property made or generated pursuant to this
Agreement, independently of the Research Programme. 

  

	 	1.27	 “Immutep Licensed Arising IP” means any Intellectual Property which is invented solely
by Immutep during the Research Programme, which has arisen directly from the use of the Merck-Serono IP. 

  

	 	1.28	 “Immutep Non-Licensed Arising IP” means any
Intellectual Property which is invented solely by Immutep during the Research Programme, which has not arisen directly from the use of the Merck-Serono IP. 

  

	 	1.29	 “Immutep Licensed Arising Patents” means any and all Patents within the Immutep
Licensed Arising IP. 

  
 4 

					
	Confidential	  		  	Execution Copy

  

	 	1.30	 “Immutep Non-Licensed Arising Patents” means
any and all Patents within the Immutep Non-Licensed Arising IP. 

  

	 	1.31	 “Immutep Background IP” means any and all Intellectual Property, which shall exclude
the Merck-Serono IP, as of the Effective Date which (a) is Controlled by Immutep or its Affiliates; and (b) relates to the Monoclonal Antibody or otherwise is necessary for the research and development of the Monoclonal Antibody and/or the
Licensed Product, and/or the commercialization of the Licensed Product. 

  

	 	1.32	 “Immutep Background Patents” means any and all Patents within the Immutep Background IP
as of the Effective Date, including Monoclonal Antibody Patents. 

  

	 	1.33	 “Immutep Intellectual Property” means any Intellectual Property owned or Controlled by
Immutep or its Affiliates as of the Effective Date and during the Term collectively, the Immutep Background IP, Immutep Know-How, the Immutep Non- Licensed Arising IP, the Immutep Licensed Arising IP, the
Immutep interest in the Joint Non-Licensed Arising IP and the Immutep interest in the Joint Licensed Arising IP, all of which shall exclude the Merck-Serono IP. 

 

	 	1.34	 “Immutep Know-How” means any Know-How owned or Controlled by Immutep or its Affiliates as of the Effective Date and/or during the Research Term. 

  

	 	1.35	 “IND” means any investigational new drug application filed with the FDA pursuant to
Part 312 of Title 21 of the U.S. Code of Federal Regulations, including any amendments thereto. References herein to IND shall include, to the extent applicable, any comparable filing(s) outside the U.S. (such as a Clinical Trial Application in the
European Union). 

  

	 	1.36	 “Indemnitee” has the meaning assigned to such term in Clause 14.3.

  

	 	1.37	 “Indication” means a distinct disease category (for example, cancer versus
inflammation) and does not mean a different type or subpopulation within the same primary disease (for example, colon cancer versus breast cancer) which shall be determined in reference to the version of the World Health Organization ICD-10 applicable as of the Effective Date such distinction to be derived from the distinct chapters I-XXII contained therein. Each chapter
sub-heading shall be treated as one indication. By way of example, as of the date of this Agreement, the applicable ICD- 10 refers to “Diseases of the musculoskeletal system and connective tissue (M00-
M99)” which is understood by the Parties to be a chapter heading. “Arthopathies (M00-M25)” is understood by the Parties to be a sub-chapter heading.

  

	 	1.38	 “INSERM Agreement” means the agreement entered into between Inserm Transfert, Universite de
Nantes and Immutep effective as of 30 April, 2007, concerning the management and exploitation of a jointly filed patent application regarding an anti-LAG-3 monoclonal
antibody and its use in the treatment of certain diseases, as amended, attached hereto at Schedule 8. 

  

	 	1.39	 “INSERM Research Collaboration Agreement” entered into between INSERM and Immutep dated
February 22, 2006 (INSERM TRANSFERT reference number 04170A10), as amended, as attached hereto at Schedule 9. 

  

	 	1.40	 “INSERM TRANSFERT” means the limited company organized under the laws of France, whose
registered headquarters is located at 7 rue Watt, 75013 PARIS, France, acting as delegate of Institut National de la Santé et de la Recherche Médicale (hereinafter referred to as “INSERM”), as laid out in more detail in the
INSERM Agreement. 

  

	 	1.41	 “Institut Gustave Roussy Agreement” means the licence agreement by and between Institut
Gustave Roussy, INSERM and ARES TRADING SA pursuant to which ARES Trading SA has the right to license certain patents and patent applications relating to LAG-3 and
know-how related thereto as stated in the first recital of the Merck-Serono Agreement. 

  
 5 

					
	Confidential	  		  	Execution Copy

  

	 	1.42	 “Intellectual Property” means Patents, Know-How,
utility models, and other like forms of protection, copyrights, database rights, rights in databases, trade names, trade or service marks (whether registered or unregistered), domain names, design rights (whether registered or unregistered),
including all applications for registration for the foregoing and all other similar proprietary rights as may exist anywhere in the world. 

  

	 	1.43	 “Invoice” means any invoice submitted to GSK by Immutep under this Agreement.

  

	 	1.44	 “Joint Licensed Arising IP” has the meaning assigned to such term in Clause 9.3.1(f).

  

	 	1.45	 “Joint Licensed Arising Patents” means any and all Patents within the Joint Licensed
Arising IP. 

  

	 	1.46	 “Joint Non-Licensed Arising IP” means any
Intellectual Property which is invented during the Research Programme which has not arisen directly from the use of the Merck-Serono IP, and which is not separable into either Immutep Non-Licensed Arising IP,
or GSK Non-Licensed Arising IP (for patent applications, to the extent that a single claim spans subject matter falling under both Immutep Non-Licensed Arising IP or GSK
Non-Licensed Arising IP). 

  

	 	1.47	 “Joint Non-Licensed Arising Patents” means any
and all Patents within the Joint Non-Licensed Arising IP. 

  

	 	1.48	 “Joint Patent Subcommittee” or “JPS” has the meaning set out in Clause
6.10. 

  

	 	1.49	 “Joint Steering Committee” or “JSC” has the meaning set out in Clause
6.1. 

  

	 	1.50	 “Know-How” means unpatented technical, scientific and
other know-how, materials and information, trade secret, knowledge, technology of a Party that is maintained as a trade secret and is not generally known except by way of any breach of this Agreement by either
Party, including, but not limited to, the items set out in Schedule 7, ideas, concepts, inventions, discoveries, data, formulae, specifications, information, materials, models, assays, analytical processes and SOPs, materials relating to assays,
analytical systems or processes, procedures for experiments and tests and results of experimentation and testing, results of research and development including laboratory records, data relating to pharmacology of products (including data relating to
toxicology, bioavailability, metabolism, metabolites and pharmacokinetics), clinical trial data, case report forms, data analyses, reports or summaries and information contained in submissions to and information from ethical committees and
Regulatory Authorities, procedures, data and reports relating to the development, supply and manufacture of drug substance and drug products. The fact that a part of a compilation of data is generally known except by way of any breach of this
Agreement by either Party shall not prevent the compilation of data as such, or any one or more of the other elements of the compilation from being Know- How, if, in the latter case, such remaining portions or elements are still being maintained as
a trade secret. 

  

	 	1.51	 “LAG-3” means the protein termed Lymphocyte Activation
Gene-3, also known as CD223, (Swiss-Prot: P18627, Genbank: NM_002286 (human ortholog)) or any variant thereof. 

  

	 	1.52	 “Licensed Product” means any one product containing the Monoclonal Antibody as a
therapeutically active ingredient, in final form for sale by prescription, over-the- counter, or any other method. 

  

	 	1.53	 “Losses” has the meaning set out in Clause 14.1. 

 

	 	1.54	 “Managed Patents” means Monoclonal Antibody Patents, Immutep
Non-Licensed Arising Patents, Immutep Licensed Arising Patents, Joint Non-Licensed Arising Patents and the Joint Licensed Arising Patents. 

 

	 	1.55	 “Materials” has the meaning set out in Clause 4.12 

  
 6 

					
	Confidential	  		  	Execution Copy

  

	 	1.56	 “Marketing Approval” means all regulatory approvals, licenses, registrations or authorizations
of any federal, state or local regulatory agency, department, bureau or other governmental entity, necessary for the manufacturing, use, storage, import, transport and sale, and in the European Union, where necessary, pay or approval of price and/or
reimbursement for Licensed Products in a regulatory jurisdiction. 

  

	 	1.57	 “Marketing Authorisation Application” means, with respect to the Licensed Product, an NDA and
all amendments and supplements thereto with respect to a pharmaceutical product necessary for Regulatory Approval of a pharmaceutical product in the United States and any marketing authorisation application or other equivalent application filed with
any other applicable Regulatory Authority. 

  

	 	1.58	 “Member” has the meaning set out in Clause 6.3. 

 

	 	1.59	 “Merck-Serono Agreement” means the licence agreement between Ares Trading S.A. and
Immutep, effective as of December 9, 2002 as amended, attached at Schedule 10. 

  

	 	1.60	 “Merck-Serono Know-How” means any and all Know-How within the Merck- Serono IP the details of which are attached hereto at Schedule 7. 

  

	 	1.61	 “Merck-Serono IP” means the Merck-Serono Know-How and
the Merck-Serono Patents. 

  

	 	1.62	 “Merck-Serono Patents” means any and all Patents within the Merck-Serono IP the details of
which are attached at Schedule 6. 

  

	 	1.63	 “Monoclonal Antibody” means any monoclonal antibody, fragment, modifications or derivative
thereof, which binds to LAG-3 and causes [***]. 

  

	 	1.64	 “Monoclonal Antibody Patents” means those Patents listed in Schedule 4; any extensions,
registrations, confirmations, reissues, supplementary protection certificates, re-examinations and renewals thereof; any provisional applications, substitutions, continuations,
continuations-in-part, divisionals and renewals thereof; any validations and revalidations; and any foreign counterparts of any of the foregoing. 

 

	 	1.65	 “NDA” means a New Drug Application (as more fully defined in Title 21 of the U.S. Code
of Federal Regulations, Clause 314.50 et seq. or its successor regulation) filed with the FDA, or the analogous application filed with any other Regulatory Authority outside the United States (including the EMA), and all amendments and
supplements thereto. 

  

	 	1.66	 “Net Sales” means with respect to any Licensed Product, the gross invoiced sales price,
exclusive of sales taxes (such as value added tax or its equivalent) of such product sold by either GSK, its Affiliates or Sub-licensees (in each case, the “Selling Party”), in finished
product form, packaged and labelled for sale, under this Agreement in arm’s length sales to Third Parties, less the following deductions, if not previously deducted, which are actually incurred, allowed, paid, accrued or specifically allocated
to the Third Party customer by the Selling Party (to the extent actually taken by such Third Party customer) on such sales for: 

  

	 	 	 [***]. 

  
 7 

					
	Confidential	  		  	Execution Copy

  

	 	 	 Any of the deductions listed above that involves a payment by GSK shall be taken as a deduction in the Calendar
Quarter in which the payment to Immutep is incurred. For purposes of calculating the Net Sales of bundled products, deductions shall be apportioned across all products in the bundle on a fair and reasonable basis, provided that the percentage rebate
or discount apportioned to the Licensed Product shall not exceed the percentage rebate or discount applied in total to the bundled products. 

  

	 	 	 Sales between GSK and its Affiliates or Sub-licensees shall be excluded
from the computation of Net Sales and no payments will be payable on such sales, except where any such Affiliate or Sub-licensee is the last entity in the distribution chain for the product and is purchasing
it for its own commercial use. In addition, Licensed Product provided to patients for compassionate use will not be included in Net Sales. The Parties agree that, in the event that either Party proposes that this definition of Net Sales be amended
to reflect changes required by the adoption of new accounting standards applicable to a Selling Party, whether due to merger, acquisition, business combination or other similar transaction with, by or into another entity or required by law, the
other Party shall consider such proposal reasonably and in good faith. 

  

	 	1.67	 “Orphan Indication” means an Indication so defined by any applicable Regulatory
Authority anywhere in the Territory. 

  

	 	1.68	 “Party” means either GSK or Immutep and Parties means both of them; 

 

	 	1.69	 “Patents” mean: 

 

	 	1.69.1	 issued and unexpired letters patent, including patent extensions, paediatric extensions, supplementary
protection certificates and any other rights, registrations, confirmations, reissues, re-examinations and renewals thereof; 

 

	 	1.69.2	 patent applications pending approval, including all provisional applications, substitutions, continuations, continuations-in-part, divisional, validations, revalidations and renewals thereof, and 

 

	 	1.69.3	 foreign counterparts of any of the foregoing. 

 

	 	1.70	 “Patent Costs” means the reasonable fees and expenses paid to outside legal counsel,
and filing, maintenance and other reasonable out-of-pocket expenses paid to Third Parties, including official fees and renewal fees paid to patent offices, in connection
with the prosecution and maintenance of Patents. 

  

	 	1.71	 “Payment Report” has the meaning assigned to such term in Clause 8.11.1.

  

	 	1.72	 “Phase I Clinical Trial” means a clinical trial of a pharmaceutical product candidate
that generally provides for the first introduction into humans of such product with the primary purpose of determining safety, metabolism and pharmacokinetic properties and clinical pharmacology of such product candidate. 

 

	 	1.73	 “Phase II Clinical Trial” means a clinical trial of a pharmaceutical product on human
subjects which is a controlled dose-ranging study designed to evaluate the efficacy and safety of a product in the target patient population. 

  

	 	1.74	 “Phase III Clinical Trial” means one or more clinical trials on sufficient numbers of
subjects, which trial(s) are designed to (a) establish that a drug is safe and efficacious for its intended use; (b) define warnings, precautions and adverse reactions that are associated with the drug in the dosage range to be prescribed;
and (c) provide substantial evidence of efficacy necessary to satisfy requirements for Regulatory Approvals (such as a combined Phase II/Phase III study). 

  
 8 

					
	Confidential	  		  	Execution Copy

  

	 	1.75	 “Receiving Party” has the meaning assigned to such term in Clause 12.1.

  

	 	1.76	 “Regulatory Approval” means, with respect to any particular jurisdiction, any and all
approvals (excluding price and reimbursement approvals), licenses, registrations, or authorizations of any country, federal, supranational, state or local regulatory agency, department, bureau or other government entity that are necessary for the
manufacture, use, storage, import, transport or sale of a product in such jurisdiction. 

  

	 	1.77	 “Regulatory Authority” or “Regulatory Authorities” means the
FDA in the U.S. and any other regulatory authority(ies) in any country in the Territory that holds responsibility for granting Marketing Approval for a product in such country(ies), in each case together with any successor(s) thereto.

  

	 	1.78	 “Research Plan” means the research plan mutually agreed by Immutep and GSK, which
defines the activities to be performed by Immutep under the Research Programme. An initial Research Plan is attached hereto as Schedule 1. Any subsequent amendments to the Research Plan shall be agreed by the JSC. 

 

	 	1.79	 “Research Programme” means any programme of discovery, identification, research,
characterization, modification and optimization carried out by Immutep with the principal goal to investigate the potential for therapeutic intervention utilizing the Monoclonal Antibody in the Field, as mutually agreed by the Parties and set out in
the Research Plan. 

  

	 	1.80	 “Research Term” means the period commencing on the Effective Date and ending on the earliest
of; 

  

	 	 	 [***]. 

  

	 	1.81	 “Safety Concern” means any of (i) the FDA or any equivalent Regulatory Authority
has issued an order or decree permanently prohibiting the further clinical use of the Licensed Product and/or Monoclonal Antibody, and/or terminate the IND under 21 CFR 312.44 on grounds of safety (or equivalent grounds under other Applicable Laws),
other than as a result of any failure of GSK or its Affiliates to comply with any applicable requirement of regulations 21 CFR 312.50 or 21 CFR 312.56 (or equivalent grounds under other Applicable Laws of other countries); or (ii) a clinical
hold has been imposed by the FDA or any other equivalent Regulatory Authority whereby the clinical trial has been definitively converted to “inactive status” under 21 CFR 312.45 on grounds of safety (or equivalent grounds under other
Applicable Laws). 

  

	 	1.82	 “Subcommittee” has the meaning assigned to such term in Clause 6.9.

  

	 	1.83	 “Sub-licensee” means any Third Party or any
Affiliate thereof to which a license is granted by a Party under Intellectual Property or Know-How owned or Controlled by the other Party in accordance with the terms of this Agreement in respect of the rights
pursuant to the research, development and commercialisation of the Monoclonal Antibody and/or the Licensed Product. 

  

	 	1.84	 “Term” has the meaning assigned to such term in Clause 15.1. 

 

	 	1.85	 “Territory” means all of the countries and territories of the world.

  

	 	1.86	 “Third Party” means any entity other than Immutep, GSK or an Affiliate of Immutep or
GSK. 

  
 9 

					
	Confidential	  		  	Execution Copy

  

	 	1.87	 “Transferee” has the meaning assigned to such term in Clause 4.12. 

 

	 	1.88	 “Transferor” has the meaning assigned to such term in Clause 4.12. 

 

	 	1.89	 “United States” or “U.S.” means the United States of America
and its territories and possessions. 

  

	 	1.90	 “Valid Claim” means a claim in an issued, in force and unexpired patent that
(a) has not been finally cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction not subject to further appeal, (b) has not been revoked, held invalid, or declared unpatentable or
unenforceable in a decision of a court or other body of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, and (c) has not been rendered unenforceable through disclaimer, abandonment, withdrawal,
dedication to the public, allowing to lapse through non-payment of renewal fees or otherwise. For clarity, a claim within a pending patent application shall not be a Valid Claim. 

 

	 	1.91	 “VAT” means the tax imposed by Council Directive 2006/112/EC of the European Community
and any national legislation implementing that directive together with legislation supplemental thereto and in particular, in relation to the United Kingdom, the tax imposed by the Value Added Tax Act of 1994 or other tax of a similar nature imposed
elsewhere instead of or in addition to value added tax. 

  

	 	1.92	 In this Agreement: 

 

	 	1.92.1	 all references to a particular Clause or Schedule shall be a reference to that Clause or Schedule in or to this
Agreement as it may be amended from time to time pursuant to this Agreement; 

  

	 	1.92.2	 the headings are inserted for convenience only and shall be ignored in construing this Agreement;

  

	 	1.92.3	 words importing the masculine gender shall include the feminine and vice versa and words in the singular
include the plural and vice versa; 

  

	 	1.92.4	 words denoting persons shall include any individual, partnership, company, corporation, joint venture, trust
association, organisation or other entity, in each case whether or not having separate legal personality; 

  

	 	1.92.5	 the words “include”, “included” and “including” are to be construed without
conveying any limitation to the generality of the preceding words; 

  

	 	1.92.6	 reference to any statute or regulation includes any modification or re- enactment of that statute or
regulation; and 

  

	 	1.92.7	 any reference to notices or consent being sought or given in writing shall require the consent or notice to be
signed by an appropriately authorised person and shall not include consents or notices conveyed by email. 

 2 GRANT OF LICENCES

  

	 	2.1	 GSK Licence 

  

	 	2.1.1	 Subject to the terms and conditions of this Agreement, Immutep hereby grants to GSK: 

 

	 	(a)	 an exclusive royalty-bearing licence (even as to Immutep, except as set forth in Clause 2.1.3(b) and Clause
2.2) under the Immutep Intellectual Property; 

  

	 	(b)	 an exclusive royalty-bearing sub-licence (even as to Immutep except as
set forth in Clause 2.1.3(b) and Clause 2.2) under the Merck-Serono IP, 

 only to research, develop, make, have made,
use, offer to sell, sell and import the Monoclonal Antibody and the Licensed Products in the Territory for use in the Field. For the avoidance of doubt, nothing in this Clause 2.1.1 shall be deemed to grant GSK any right for GSK to research,
develop, make, have made, use, offer to sell, sell and import any compounds covered or claimed in the Immutep Intellectual Property, and/or the Merck-Serono IP other than the Monoclonal Antibody and/or the Licensed Product. 

  
 10 

					
	Confidential	  		  	Execution Copy

  

	 	2.1.2	 GSK shall have the right to grant sub-licences under the rights and
licences granted to it under Clause 2.1.1, without seeking the prior written consent of Immutep. 

  

	 	2.1.3	 The rights granted to GSK pursuant to Clause 2.1.1 shall not include: 

 

	 	(a)	 the rights of INSERM and the parties to the INSERM Agreement other than Immutep pursuant to the INSERM
Agreement to the extent that the obligations of Immutep to GSK pursuant to Clause 2.1.1 and Clause 7 are not otherwise affected; and 

  

	 	(b)	 the rights of Immutep under the Immutep Intellectual Property and Merck- Serono IP to the extent that the
obligations of Immutep to GSK pursuant to Clause 2.1.1 and Clause 7 are not affected. 

  

	 	2.2	 Immutep Rights and Obligations 

 

	 	2.2.1	 Notwithstanding Clause 2.1, Immutep shall have a non-transferable right
under the Immutep Intellectual Property solely to the extent necessary or useful to discharge its obligations in relation to the Research Programme. 

  

	 	2.2.2	 GSK hereby grants to Immutep a non-exclusive licence to use the GSK
Background IP and GSK Arising IP solely to the extent necessary or useful to discharge Immutep’s obligations in relation to the Research Programme. This licence shall not be sublicenseable without the prior consent of GSK, which may be
withheld. 

  

	 	2.3	 Sublicensing. To the extent either Party is permitted to grant
sub-licences under the licences granted to it under this Clause 2, such Party shall have the right to grant such sub-licences through multiple tiers of Sub-licensees; provided that: 

  

	 	2.3.1	 any such sub-licence is consistent with and subject to the terms of
this Agreement and shall terminate automatically upon termination of the corresponding licence hereunder; and 

  

	 	2.3.2	 neither Party shall be relieved of its obligations pursuant to this Agreement as a result of such sub-licence; 

  

	 	2.3.3	 each such Party permitted to grant sub-licenses shall procure a written
agreement from any Sub-licensee that its rights under: 

  

	 	(a)	 such sub-licence shall comply in all respects with such Party’s
obligations under this Agreement; and 

  

	 	(b)	 such sub-licence shall comply in all respects with such Party’s
obligations under the Merck-Serono Agreement or under the INSERM Agreement, as applicable. 

  

	 	2.3.4	 where GSK grants a sub-licence under the Immutep Intellectual Property
and/or the Merck Serono IP to a Third Party, GSK shall ensure that: 

  

	 	(a)	 any such Sub-licensee shall not be granted rights that exceed the scope
of the rights granted to GSK under this Agreement with respect to the Immutep Intellectual Property and/or Merck Serono IP; 

  

	 	(b)	 prior to the execution of any sub-licence agreement relating to the
Immutep Intellectual Property, GSK shall provide IMMUTEP with notification of the identity and address of the Sub-Licensee, as well as such terms of the licence as GSK deems reasonably necessary, for approval
by INSERM, which shall not be withheld except if INSERM TRANSFERT gives written demonstration that the prospective licence to Sub-Licensee affects its legitimate interests. After [***] of the above-mentioned
notification, the absence of response from IMMUTEP shall be considered as an approval; and 

  
 11 

					
	Confidential	  		  	Execution Copy

  

	 	(c)	 promptly following the execution of any sub-licence agreement with any
Sub-licensee, GSK shall provide IMMUTEP with a signed copy of the sub-licence agreement with such provisions redacted which GSK deems reasonably necessary. Any information disclosed to IMMUTEP shall constitute the Confidential Information of GSK,
however IMMUTEP is hereby duly authorised by GSK to provide INSERM TRANSFERT with a signed copy of such sub-licence agreement provided that IMMUTEP notifies INSERM that such
sub-licence agreement constitutes the Confidential Information of IMMUTEP as defined in the INSERM Agreement. 

  

	 	2.4	 No Implied Licenses. No licence or other right is or shall be created or granted hereunder by
implication, estoppel or otherwise. All such licences and rights are or shall be granted only as expressly provided in this Agreement. 

  

	 	2.5	 In Licenses. The licenses granted by IMMUTEP to GSK under this Agreement are subject to the terms and
conditions of the Merck-Serono Agreement and of the INSERM Agreement that IMMUTEP provides to GSK hereunder in Schedule 8 and in Schedule 10. GSK, as a Sub-licensee, agrees to be bound by the terms and
conditions of the Merck-Serono Agreement (as attached in Schedule 10) only to the extent that they are applicable to a Sub-licensee. For clarity, GSK does not agree to be bound by any subsequent amendment to
the Merck-Serono Agreement from the Effective Date. 

 3 RIGHTS AND OBLIGATIONS OF GSK 

 

	 	3.1.1	 GSK will use Commercially Reasonable Endeavours to develop and commercialise one (1) Licensed Product
under its licence in Clause 2.1. This obligation shall not prevent GSK from exercising any right to develop and commercialise additional Licensed Product(s) claimed by the Immutep Intellectual Property under the terms of this Agreement.

  

	 	3.1.2	 GSK shall have full control, authority and responsibility for the development of the Licensed Product in the
Field within the Territory. 

  

	 	3.1.3	 GSK shall have full control, authority and responsibility for manufacturing the Monoclonal Antibody and the
Licensed Product in the Field within the Territory. 

  

	 	3.1.4	 GSK shall have full control, authority and responsibility for the commercialisation of the Licensed Product in
the Field within the Territory (which shall for the avoidance of doubt include the full control, authority and responsibility to make, have made, market, use, import, offer to sell, and sell the Licensed Product). GSK shall have final
decision-making authority, in its sole discretion, relating to the commercialisation of the Licensed Product in the Field in the Territory, including pricing and reimbursement for the Licensed Product, product advertising and promotional materials,
the Licensed Product packaging, sales force training and all interactions with Regulatory Authorities regarding the commercialisation of the Licensed Product including as applicable those related to recall or market withdrawal of the Licensed
Product. All Regulatory Approvals shall be owned and held by GSK, its Affiliates or Sub-licensees both during and after the Term. GSK shall have sole authority and responsibility for distributing and booking
all sales in the Territory. 

  

	 	3.1.5	 Notwithstanding any other provision of this Agreement, GSK shall have the right, in its sole discretion,
immediately and permanently to discontinue development, manufacture and commercialisation of the Licensed Product without further payment to Immutep (except any payment accruing prior to this time and unpaid) or to take other reasonable action,
including, without limitation instituting a recall of the Licensed Product. In such event that GSK decides to terminate the development and/or commercialisation of the Monoclonal Antibody and/or Licensed Product, then such decision shall be taken in
accordance with Clause 3.4 and the provisions of Clause 15 shall apply. 

  
 12 

					
	Confidential	  		  	Execution Copy

  

	 	3.2	 Development Costs. GSK, its Affiliates and/or Sub-licensees, as
applicable, shall bear all costs for the development of the Licensed Product in the Field and for the manufacture and commercialisation of the Licensed Product in the Field within the Territory. 

 

	 	3.3	 Reports. GSK shall provide reasonable progress updates to Immutep on the status of the
Licensed Product within [***] of the end of each Calendar Year which shall constitute Confidential Information of GSK. Immutep shall have the right to provide INSERM TRANSFERT and Ares Trading SA with information derived from such reasonable
progress updates, as required under the INSERM Agreement and the Merck-Serono Agreement respectively, and such information shall constitute Confidential Information of GSK provided however, that with respect to the obligations of Immutep under the
Merck-Serono Agreement, Immutep shall not disclose to Ares Trading S.A. any Confidential Information of GSK including the items contained in this Clause 3.3 without the prior written approval of GSK. 

 

	 	3.4	 Cessation of Development. In the event that GSK formally
decides by way of a public statement or a documented decision by a GSK internal research and development investment committee to cease all development, manufacture and/or commercialisation of all Licensed Products and/or this Agreement, it shall so
notify Immutep as soon as reasonably practicable thereafter. Such notification in accordance with this Clause 3.4 shall be deemed to be a notice of termination in respect of all the Licensed Products in accordance with Clause 15.

 4 RESEARCH COLLABORATION 
  

	 	4.1	 Overview. Pursuant to this Agreement and as further provided in this Clause 4, during the
Research Term Immutep will undertake an agreed collaborative Research Programme as laid out in the Research Plan, under the supervision of the JSC. The primary goal of the Research Programme is to investigate the potential for therapeutic
intervention utilising the Monoclonal Antibody in the Field, for further development and commercialisation by GSK under the licence granted to GSK pursuant to Clause 2.1 above. 

 

	 	4.2	 Research Plan. An initial outline Research Plan has been agreed by the Parties and is attached hereto as
Schedule 1 to the Agreement. The Research Plan may be supplemented or amended from time to time pursuant to Clause 6.1.2. 

  

	 	4.3	 Conduct of Research Plan. 

 

	 	4.3.1	 Immutep shall use its Commercially Reasonable Endeavours to undertake all the activities allotted to it in the
Research Plan, and to complete such activities in accordance with any timelines set out in the Research Plan. Immutep shall perform its activities under the Research Plan at all times in material compliance with all Applicable Laws and in accordance
with good scientific and clinical practices. For clarity, Immutep shall use personnel with all necessary skills and experience as are required to accomplish efficiently and expeditiously the objectives of the Research Programme as set forth in the
Research Plan in good scientific manner and in compliance with all material respects with all Applicable Laws. 

  

	 	4.3.2	 Without limiting the above, Immutep further agrees to perform its activities under the Research Plan at all
times in material compliance with those GSK policies identified in this Agreement. 

  
 13 

					
	Confidential	  		  	Execution Copy

  

	 	4.3.3	 Immutep acknowledges the importance to GSK of ensuring that the Research Programme is undertaken in accordance
with the following good data management practices (“Good Data Management Practices”): 

  

	 	(i)	 Data is being generated using sound scientific techniques and processes; 

 

	 	(ii)	 Data is being accurately recorded in accordance with good scientific practices by persons conducting Research
Programme hereunder; 

  

	 	(iii)	 Data is being analyzed appropriately without bias in accordance with good scientific practices;

  

	 	(iv)	 Data and results are being recorded in accordance with GSK guidelines in a GSK lab notebook (provided by GSK),
and such lab notebooks are being stored securely and can be easily retrieved, and 

  

	 	(v)	 Data trails exist to easily demonstrate and/or reconstruct key decisions made during the conduct of the
Research Programme, presentations made about the Research Programme and conclusions reached with respect to the Research Programme. 

  

	 	4.3.4	 Immutep agrees that it shall carry out the Research Programme and collect and record any data generated
therefrom in a manner consistent with the specific requirements set forth in the Research Plan. At any time during the term of this Agreement, GSK may request changes to the specific requirements set forth in the Research Plan, where GSK reasonably
believes such changes are required to ensure that the Research Programme is undertaken in compliance with Good Data Management Practices. 

  

	 	4.3.5	 GSK shall be permitted, in its sole discretion and at no additional charge to GSK, to undertake on-site compliance audits of Immutep’s Good Data Management Practices, as provided for in the Research Programme, on providing Immutep with [***]written notice of GSK’s intent to do so and subject to all
personnel conducting such audit signing a confidentiality undertaking acceptable to Immutep, abiding by all of Immutep’s site access rules and not disrupting or interfering with Immutep’s day-to-day business. 

  

	 	4.3.6	 If GSK determines during the audit that Immutep has not conducted the Research Programme under Good Data
Management Practices, GSK will inform Immutep and Immutep will have [***] to rectify the identified issue. If Immutep does not or is unable to rectify the issues identified by GSK, GSK may chose to terminate the Research Programme on [***] written
notice to Immutep. Termination of the Research Programme by GSK, shall not entitle GSK to terminate this Agreement pursuant to Clause 15.2.1. 

  

	 	4.3.7	 If Immutep commits a material breach of any of Immutep’s obligations pursuant to this Clause 4, and fails
to cure such material breach within [***] of receipt of a written notice from GSK as to the material breach and requiring remedy, or if cure cannot be reasonably effected within such [***] period, delivery by Immutep of a plan for curing such
material breach that is sufficient to effect a cure within a reasonable timeframe, with assurances acceptable to GSK, Immutep shall thereafter carry out the plan and cure the material breach within the agreed timeframe. If Immutep has not cured the
material breach accordingly, then, GSK may terminate the Research Programme immediately upon notice to Immutep.. Termination of the Research Programme by GSK, shall not entitle GSK to terminate this Agreement pursuant to Clause 15.2.1.

  
 14 

					
	Confidential	  		  	Execution Copy

  

	 	4.4	 Termination of the Research Programme. 

 

	 	4.4.1	 GSK may terminate the Research Programme pursuant to Clause 15.2.1 and Clause 15.2.2 and/or pursuant to a
Change of Control, and such termination shall not affect this Agreement, which shall continue to remain in full force and effect. Upon such termination of the Research Programme, Immutep shall provide a final report in accordance with Clause 4.6 and
shall return to GSK, or destroy, all Confidential Information of GSK, in accordance with Clause 4.7. For clarity, the licence granted to GSK pursuant to Clause 2.1 of this Agreement shall survive the termination of the Research Programme and
continue on the terms of this Agreement. 

  

	 	4.4.2	 Immutep may terminate the Research Programme without cause upon the provision of a [***] written notice to GSK
and upon the expiry or termination of the Research Programme, Immutep shall provide a final report in accordance with Clause 4.6 and shall return to GSK, or destroy, all Confidential Information of GSK, in accordance with Clause 4.7. If Immutep
terminates the Research Programme within [***] following any payment made by GSK to Immutep pursuant to Clause 4.5, Immutep shall re-imburse to GSK prorata temporis the most recent payment made by GSK to Immutep pursuant to Clause 4.5.

  

	 	4.5	 Costs of Research. Subject to the remainder of this Clause 4.5
and the provisions of Clause 16 or unless expressly agreed to the contrary in writing by the unanimous agreement of all JSC Members, Immutep shall be responsible for the costs that it incurs in performing the activities allotted to it in the
Research Plan. Notwithstanding, GSK shall pay to Immutep [***] within [***] following receipt by GSK of an Invoice from Immutep on or after the Effective Date. GSK shall subsequently pay to Immutep [***] within [***] following receipt by GSK of an
Invoice from Immutep on or after the first annual anniversary of the Effective Date. However, if GSK terminates the Research Programme pursuant to this Agreement after the first payment of [***] and prior to the first anniversary , GSK shall not be
required to pay Immutep the second payment of [***]. 

  

	 	4.6	 Reports. Immutep shall provide reasonable progress updates to the JSC on the status of its
activities under the Research Plan, including as and where appropriate summaries of data generated and a timetable for completion of relevant activities. Immutep shall use reasonable endeavours to provide any such written summaries to JSC members at
least [***] in advance of the applicable JSC meeting. At the completion of the Research Programme, Immutep shall submit to GSK a final report within [***] following the completion of the Research Programme acceptable to GSK in all respects. For
clarity, the information summaries and reports provided to GSK under this Clause 4.6 shall constitute the Confidential Information of GSK. 

  

	 	4.7	 Provision of Information. Immutep will provide to GSK all information that is generated in the course of
its activities under the Research Plan, or otherwise in relation to the Monoclonal Antibody generated by Immutep. The provision of all such information shall be performed in a timely manner to allow for disclosure to regulatory authorities in
accordance with all regulatory deadlines, promote compliance with the timelines set forth in any agreed plan, and in order to facilitate each Party’s decision-making in connection with the JSC meetings and to monitor the obligations of Immutep.
Within [***] following the termination or expiry of the Research Programme, Immutep shall return to GSK or destroy, at GSK’s request, all Confidential Information of GSK except that Immutep shall be permitted to retain one copy of all
Confidential Information of GSK so that any continuing legal obligations may be determined. 

  
 15 

					
	Confidential	  		  	Execution Copy

  

	 	4.8	 Subcontracting. Immutep may, as far as is set out in the Research Plan, fulfil its
obligations under the Research Plan through sub-contractors, in accordance with the provisions of this Clause 4.8, however, if Immutep plans to subcontract its obligations under the Research Plan, it shall
obtain GSK’s prior written consent, which may be withheld. Immutep acknowledges that the appointment of a subcontractor shall not relieve it of its obligation to carry out, or procure the carrying out of that part of the Research Programme or
this Agreement; 

  

	 	4.8.1	 Any subcontractor engaged by Immutep to perform an obligation set forth in this Agreement shall meet the
qualifications required by Immutep for the performance of the subcontracted work. For clarity, any subcontractor to be engaged under this Agreement shall not be appointed by Immutep unless they possess all necessary skills and experience as are
required to efficiently and expeditiously accomplish the subcontracted responsibilities to such standards as are necessary to comply with its obligations under this Agreement. Notwithstanding the preceding, Immutep shall remain responsible and
obligated for such activities and shall in all cases retain or obtain exclusive Control (i.e., either ownership or an exclusive, sub- licensable licence) of any and all Intellectual Property created by (or
used with Immutep’s permission by) such subcontractor directly related to such subcontracted activity, at the sole cost and expense of Immutep. For clarity, Immutep shall procure that any subcontractor appointed under this Agreement shall be
held to confidentiality undertakings equivalent to those enforceable against Immutep under this Agreement. 

  

	 	4.9	 Ethical Care of Animals. 

 

	 	4.9.1	 Immutep agrees to comply with all relevant statutes, legislation, regulations and guidelines for the care,
welfare and ethical treatment of animals used in research in the country where the research is being performed. In conducting any research involving the use of animals, Immutep further agrees to comply with the “3R” Principles -
reducing the number of animals used, replacing animals with non-animal methods whenever possible and refining the research techniques used. All work must be conducted in adherence to the core principles for
animals on research studies identified below. Local customs, norms, practices or laws may be additive to the core principles, but Immutep agrees to comply, as a minimum, with these core principles: 

 

	 	(a)	 Access to species appropriate food and water, 

 

	 	(b)	 Access to species specific housing, including species appropriate temperature and humidity levels,

  

	 	(c)	 Access to humane care and a program of veterinary care, 

 

	 	(d)	 Ability to demonstrate species specific behaviour, 

 

	 	(e)	 Adherence to principles of replacement, reduction and refinement in the design of in vivo
studies, 

  

	 	(f)	 Study design reviewed by institutional ethical review panel, 

 

	 	(g)	 Commitment to minimizing pain and distress during in vivo studies, and 

 

	 	(h)	 Work performed by appropriately trained staff; 

 

	 	4.9.2	 Immutep shall permit GSK to conduct reasonable inspections (not audits) if announced in advance by written
notice, in order for GSK to confirm adherence to the above principles and guidelines. To the extent that any material deficiencies are identified as the result of such inspection, Immutep shall endeavour in good faith to take reasonable and
practical corrective measures to remedy any such material deficiencies. 

  
 16 

					
	Confidential	  		  	Execution Copy

  

	 	4.10	 Use of Human Tissue. 

 

	 	4.10.1	 Immutep represents and warrants that any human biological samples used in the Research Programme have been
obtained and will be stored and used in accordance with all relevant laws including, but not limited to, the Human Tissue Act 2004 or the equivalent French regulations (including but not limited to L.
n°2004-800 et L. n° 94-654), and any generally accepted ethical guidelines in particular the MRC Guidelines entitled “Human Tissue and Biological Samples
for use in Research” regarding the collection, use and transport of human tissue. 

  

	 	4.11	 Ethical Standards. 

 

	 	4.11.1	 Human Rights 

  

	 	(a)	 Unless otherwise required or prohibited by law, the Immutep warrants, to the best of its knowledge, that in
relation to the performance of this Agreement: 

  

	 	(i)	 it does not employ engage or otherwise use any child labour in circumstances such that the tasks performed by
any such child labour could reasonably be foreseen to cause either physical or emotional impairment to the development of such child; 

  

	 	(ii)	 it does not use forced labour in any form (prison, indentured, bonded or otherwise) and its employees are not
required to lodge papers or deposits on starting work; 

  

	 	(iii)	 it provides a safe and healthy workplace, presenting no immediate hazards to its employees. Any housing
provided by Immutep to its employees is safe for habitation. Immutep provides access to clean water, food, and emergency healthcare to its employees in the event of accidents or incidents in the workplace; 

 

	 	(iv)	 it does not discriminate against any employees on any ground (including race, religion, disability or gender).

  

	 	(v)	 it does not engage in or support the use of corporal punishment, mental, physical, sexual or verbal abuse and
does not use cruel or abusive disciplinary practices in the workplace; 

  

	 	(vi)	 it pays each employee at least the minimum wage, or a fair representation of the prevailing industry wage,
(whichever is the higher) and provides each employee with all legally mandated benefits; 

  

	 	(vii)	 it complies with the laws on working hours and employment rights in the countries in which it operates;

  

	 	(viii)	 it is respectful of its employees right to join and form independent trade unions and freedom of association.

  

	 	(b)	 Immutep agrees that it is responsible for controlling its own supply chain and that it shall encourage
compliance with ethical standards and human rights by any subsequent supply of goods and services that are used by Immutep when performing its obligations under this Agreement. 

 

	 	(c)	 Immutep shall ensure that it has ethical and human rights policies and an appropriate complaints procedure to
deal with any breaches of such policies. 

  

	 	4.12	 Transfer of Materials. In the event that either GSK or Immutep
(the “Transferor”) agrees to transfer any biopharmaceutical, biological or chemical material (“Material”) to Immutep or GSK (as the case may be) (the “Transferee”) for use within the Research
Programme such transfer shall take place in accordance with the following provisions: 

  
 17 

					
	Confidential	  		  	Execution Copy

  

	 	4.12.1	 Such transfer shall be recorded using the material transfer record form set out in Schedule 5, which the
Transferor shall complete and submit to the Transferee for counter-signature prior to the transfer of the material. GSK and Immutep agree that one member of the JSC from each Party together with any further individual notified by the JSC (as the
case may be) to the other shall be authorised to execute such form on behalf of the respective Party. 

  

	 	4.12.2	 Both Parties warrant that they have the full right and authority to transfer the Materials to the Transferee
for use within the Research Programme. 

  

	 	4.12.3	 Materials and related information provided by Transferor will remain the property of Transferor or remain under
the control of Transferor and will be kept securely by Transferee and will not be provided by Transferee, without the prior written consent of Transferor to any Third Party. 

 

	 	4.12.4	 The Transferee shall only use the Material for the purpose of the performing the applicable work as laid out
under the Research Plan detailed in Schedule 1 and use the Materials in accordance with all applicable laws, regulations and governmental guidelines. 

  

	 	4.12.5	 The Transferee shall not, save as necessary for the conduct of work as laid out under the Research Plan, use
the Material in any human or animal subjects. 

  

	 	4.12.6	 The Transferee acknowledges that the Material is experimental in nature and provided “as is” and that
the Transferor makes no representation or extends no warranty of any kind with respect to the Material and hereby disclaims all warranties, either express or implied, including, but not limited to, any warranty of merchantability, fitness for a
particular purpose or that their use does not or will not infringe any patent rights of third parties. 

  

	 	4.12.7	 The Transferee shall use the Material at its own risk and in accordance with applicable laws and regulations
and any safety instructions provided by the Transferor. 

  

	 	4.12.8	 The Transferee shall at the election of the Transferor following completion of the purpose for which the
Material was transferred destroy or return the Material. 

 5 TECHNOLOGY TRANSFER TO GSK 

 

	 	5.1	 Immutep will as soon as reasonably practicable, provide to GSK at no cost to GSK, and to the extent GSK
reasonably requires for the exercise by GSK of the rights granted under Clause 2 as follows: 

  

	 	5.1.1	 Within [***] following the Effective Date, all Immutep Background IP and Merck-Serono IP relating to the
Monoclonal Antibody and the Research Programme, (which will include such of the tech transfer requirements set out in Schedule 3 to the extent that such information is in Immutep’s possession and Control at the Effective Date) in an
electronically editable format suitable for electronic Common Technical Document (eCTD) submission (where available to Immutep in such format at the Effective Date) or as otherwise agreed between the Parties, together with any analytical
methodologies (including applicable reference standards, test methods and specifications), the Monoclonal Antibody manufacturing processes, regulatory documentation (paper or electronic, as agreed between the Parties), filings and correspondence,
patent information, all preclinical and clinical data and reports (in PDF format) in Immutep’s possession and Control at the Effective Date; and 

  
 18 

					
	Confidential	  		  	Execution Copy

  

	 	5.1.2	 such Know-How relating to the manufacture of the Monoclonal Antibody as
is in the possession and Control of Immutep and as may reasonably be required by GSK for the manufacture of the Monoclonal Antibody; 

  

	 	5.1.3	 technology transfer services sufficient to facilitate a smooth transfer of such information, materials and data
as set out in this Clause 5; 

  

	 	5.1.4	 Immutep obtains all necessary consents and approvals required by any person or entity to disclose to GSK any
research data generated under or in connection with the INSERM Research Collaboration Agreement related to the Monoclonal Antibody; and 

  

	 	5.1.5	 Notwithstanding anything to the contrary contained herein, the Merck- Serono
Know-How transferred to GSK shall be subject to the provisions of Clause 12 of this Agreement and GSK shall treat such Know-How as the Confidential Information of
Immutep. 

 6 GOVERNANCE OF THE RESEARCH COLLABORATION AND THE DEVELOPMENT PROGRAMME 

 

	 	6.1	 Promptly and in any event within [***] after the Effective Date, the Parties shall establish and convene
a committee (the “Joint Steering Committee” or “JSC”), which shall oversee and manage the progress of the Research Programme and provide a forum to review development matters. The JSC
shall survive the expiry or early termination of the Research Term and shall continue until no Licensed Product is under development, provided however, that GSK shall have the option to terminate the JSC upon a Change of Control of Immutep. In
particular the JSC shall have responsibility for: 

  

	 	6.1.1	 reviewing the results of the Research Programme and monitoring their overall progress; 

 

	 	6.1.2	 approving any supplements or modifications to the Research Plan; and 

 

	 	6.1.3	 monitoring and approving the exchange of relevant information and Materials between the Parties as required for
the performance of the Research Plan using the Material Transfer Record Form in Schedule 5; 

  

	 	6.1.4	 attempting to resolve any disputes regarding proposed publications containing Confidential Information;

  

	 	6.1.5	 facilitating communication and providing a forum to review development matters pertaining to any Licensed
Product. Such review shall include, upon GSK’s reasonable request, input by Immutep into GSK regulatory reports during the development of any Licensed Product; and 

 

	 	6.1.6	 such other responsibilities as may be assigned to the JSC pursuant to this Agreement or as may be mutually
agreed upon by the Parties from time to time; provided, however that the JSC shall not have the power to amend or modify this Agreement other than the Research Plan. 

 

	 	6.2	 Notwithstanding the above, 

 

	 	6.2.1	 GSK shall have final decision making authority on all decisions relating to the termination of the Research
Programme, provided that GSK’s rights relating to termination are exercised in accordance with Clause 15. 

  

	 	6.2.2	 For the avoidance of doubt, except in relation to the activities to be performed under the Research Plan, GSK
shall have the sole decision making authority in relation to any decisions taken in respect of the research, development, manufacture and commercialization of any Licensed Product. For clarity, GSK shall make all decisions regarding the development
of any Licensed Product independently of the JSC. 

  
 19 

					
	Confidential	  		  	Execution Copy

  

	 	6.3	 Membership. The JSC shall be comprised of an equal number of representatives from each of the Parties
(the “Members”). The exact number of such representatives from each Party shall be two (2), or such other number as the Parties may mutually agree. Each Party may replace any or all of its representatives on the JSC at any time upon
written notice to the other Party in accordance with Clause 17. Any Member of the JSC may designate a substitute to attend and perform the functions of that Member at any meeting of the JSC. Each Party may, in its reasonable discretion, invite non-Member representatives of such Party to attend meetings of the JSC, as a non-voting participant, provided that such persons are bound by the confidentiality obligations of
Clause 12. A chairperson shall be appointed by GSK to oversee the operation of the JSC and the preparation of the minutes as set forth in Clause 6.6 (the “Chairperson”). 

 

	 	6.4	 Meetings of the JSC. During the Research Term, the JSC shall meet once each Calendar Quarter, or more or
less frequently as the Parties may mutually deem appropriate. At least half of the meetings of the JSC in any Calendar Year shall be held in person, unless the Parties mutually agree otherwise, and such in person meetings shall alternate between UK-based offices of GSK and the France-based offices of Immutep, or such other place as the Parties may agree. The members of the JSC also may convene or be polled or consulted from time to time by means of
telecommunications, video conferences, electronic mail or correspondence, as deemed necessary or appropriate. Outside of the Research Term, the JSC shall meet annually within [***] of the receipt of the annual progress report from GSK under Clause
4.6, whether remotely by teleconference or in person, as may be determined by the Parties from time to time. 

  

	 	6.5	 Decision-making. Except as otherwise expressly provided in this Agreement, decisions of the JSC shall be
made by unanimous vote of a quorum of the Members, with each Party having one (1) vote. The presence of at least two (2) Members representing each Party (i.e. a total of at least four (4) Members) shall constitute a quorum. The
Members shall use their reasonable endeavours to reach agreement on any and all matters to be determined or resolved by the JSC. In the event of any disagreement at the JSC, GSK shall have sole decision making authority on all decisions relating to
the progress or direction of the Research Programme, provided that GSK shall only use its sole decision making authority to supplement or modify the Research Plan where such supplement or modification does not materially increase the activities to
be performed by Immutep under the Research Plan, or materially increase their cost, or take the Research Programme outside of the scope as described in Clause 4.1. 

 

	 	6.6	 Minutes. The Parties shall be alternately responsible for preparing and circulating minutes within [***]
after each meeting setting forth in respect of the Research Programme, amongst other things, a list of topics of discussion at the meeting and a list of any actions, decisions or determinations approved and a list of any issues and actions to be
resolved pursuant to Clause 6.7, such that the Party who did not prepare the agenda at the previous meeting shall prepare the agenda for the subsequent meeting. With the sole exception of specific items of the meeting minutes to which the Members
cannot agree and which are escalated as provided in Clause 6.7, the Parties shall ensure that the definitive minutes of all JSC meetings are finalized within [***] of the date of the relevant meeting of the JSC. If at any time during the preparation
and finalization of the JSC minutes, the Parties do not agree on any issue with respect to the minutes, such issue shall be resolved by the escalation process as provided in Clause 6.7. The decision resulting from the escalation process shall be
recorded in amended minutes for such meeting. 

  
 20 

					
	Confidential	  		  	Execution Copy

  

	 	6.7	 Dispute Resolution by Executive
Officers. At any time, if the JSC is unable to reach a consensus decision and the subject matter of such decision is not subject to GSK’s sole decision-making authority (and not subject to referral to the Senior IP
Representatives pursuant to Clause 10.1, within [***] (or sooner if required) after it has met and attempted to reach such decision, then either Party may, by written notice to the other, have such matter referred to the Chief Executive Officer of
Immutep, and the Senior Vice President of Biopharmaceutical R&D of GSK, or such other person designated by GSK (being an employee of GSK or an Affiliate of GSK and more senior than the most senior GSK Member of the JSC) from time to time
(collectively, the “Executive Officers”), for resolution. The Executive Officers shall meet promptly to discuss the matter submitted and to determine a resolution. If the Executive Officers are unable to determine a resolution in a
timely manner, which shall in no case be more than [***] after the matter was referred to them, then GSK shall have the deciding vote on the matter. 

  

	 	6.8	 Limitation on Final Decision-Making Authority. In no event shall GSK exercise its final decision-making
authority in a manner that would have the effect of modifying, amending or would otherwise be in conflict with, the terms or provisions of this Agreement (including applicable definitions). 

 

	 	6.9	 Subcommittee(s). From time to time, the JSC, acting unanimously, may establish one or more
subcommittees to oversee particular activities, as it deems necessary or advisable (each, a “Subcommittee”). Each Subcommittee shall consist of such number of members as the JSC determines is appropriate from time to time; provided
that, unless the JSC shall unanimously agree otherwise, each Party shall have the same number of representatives on each Subcommittee. Such members shall be individuals with expertise and responsibilities in one or more of the areas of preclinical
development, clinical development, Patents, process sciences, manufacturing, regulatory affairs, product development or product commercialization, as applicable to the stage of development of the project or activity. Except as otherwise expressly
provided in this Agreement, decisions of a Subcommittee shall be made by unanimous vote of a quorum of the members of the Subcommittee, with each Party having one (1) vote. 

 

	 	6.10	 The Joint Patent Subcommittee. Promptly after
the first JSC meeting, the Parties shall establish a Joint Patent Subcommittee (a “JPS”) to oversee the Immutep Background Patents, the Collaboration Patents and the subject matter of Clause 8.8 only. The JPS shall be comprised of
two (2) representatives (or such other number of representatives as the Parties may agree) from each of GSK and Immutep. The JPS will report to the JSC and will serve as the forum to review and discuss and receive, in the first instance, matters
relating to the Immutep Background Patents, the Collaboration Patents and the subject matter of Clause 8.8 in accordance with the provisions of Clause 9 and the other relevant provisions of this Agreement. The JPS shall survive the expiry or early
termination of the Research Term and continue for the Term of this Agreement. 

  

	 	6.11	 Alliance Managers. Either Party may appoint one (1) alliance manager to
serve as the point person for communications between the Parties on matters arising under this Agreement (an “Alliance Manager”). Each Alliance Manager shall be primarily responsible for promoting communications and
collaboration between the Parties and internally within the Parties. Each Alliance Manager shall also be responsible for: 

  

	 	6.11.1	 facilitating coordination among the various functional representatives of Immutep or GSK, as appropriate;

  

	 	6.11.2	 providing single-point communication for seeking consensus; and 

 

	 	6.11.3	 each Alliance Manager may attend all JSC and JPS meetings and any other Subcommittee meetings of any other
Subcommittee that may be convened under the Agreement, in each case as a non-voting participant, provided that such Alliance Managers are bound by the confidentiality obligations of Clause 12.

  
 21 

					
	Confidential	  		  	Execution Copy

  

 7 EXCLUSIVITY 
  

	 	7.1	 Except as permitted by the Research Programme, for so long as there is any Monoclonal Antibody or
Licensed Product in research, development and/or commercialization, as applicable, by GSK or any of its respective Affiliates, Sub- licensees or permitted assignees at any time, during the Term of this Agreement, Immutep shall not:

  

	 	7.1.1	 develop or commercialise, either independently or with any Third Party; or 

 

	 	7.1.2	 offer any right or licence under Immutep Intellectual Property, to any Affiliate or any Third Party except in
accordance with this Agreement, 

  

	 	 	 in each case above, with respect to any molecule, including a Monoclonal Antibody, or fragment thereof, that
has the effect of [***] for any Indication in the Field within the Territory. 

 8 MILESTONES AND ROYALTIES; PAYMENTS 

 

	 	8.1	 Upfront Payment to Immutep. In part consideration for the licences granted by Immutep to GSK within the
Field pursuant to Clause 2, GSK shall pay a one-time- only fee of [***] no later than [***] after receipt by GSK of an Invoice from Immutep issued on or after the Effective Date. 

 

	 	8.2	 Milestone Payments for Achievement of
Milestone Events. In part consideration for the licences granted by Immutep to GSK pursuant to Clause 2, GSK shall pay to Immutep in accordance with Clause 8.3 each of the milestone payments as set out below, if the
relevant milestone event is achieved with respect to the Licensed Product as indicated in the table below: 

  

					
	 Milestone [***]
	  	
1st Indication
	  	
2nd Indication

	First dose in Phase I Clinical Trial (step A)	  	[***]	  	[***]
			
	First dose in Phase II Clinical Trial (step B)	  	[***]	  	[***]
			
	First dose in Phase III Clinical Trial (step C)	  	[***]	  	[***]
			
	Acceptance of a Marketing Authorisation Application in the U.S. in respect of a Licensed Product	  	[***]	  	[***]
			
	Acceptance of Marketing Authorisation Application in respect of a Licensed Product by the EMA or in the first of the following countries: UK, France, Germany, Italy and Spain	  	[***]	  	[***]
			
	First Commercial Sale in the U.S. in respect of a Licensed Product	  	[***]	  	[***]
			
	First Commercial Sale in respect of a Licensed Product in the first of the following countries: the UK, France, Germany, Italy and Spain.	  	[***]	  	[***]

  
 22 

					
	Confidential	  		  	Execution Copy

  

	 	8.2.1	 For the avoidance of doubt, milestone payments shall only be payable once according to the table in Clause 8.2
above for each of the first two indications and no payment shall be due for any milestone event which is not achieved. Milestone payments shall not be payable for any Indication which is an Orphan Indication. However, milestone payments shall be
payable in respect of the first and second Indications which are not Orphan Indications. The maximum therefore payable under Clause 8.2 above is [***]. Milestone payments are not creditable and non-refundable.

  

	 	8.3	 Payment of Milestone Payments. GSK shall notify
Immutep of the achievement of a milestone event within [***] of its achievement. GSK shall pay Immutep the relevant milestone payment within [***] of receipt by GSK of an Invoice from Immutep following the achievement of such milestone. If, for any
reason, GSK omits any one or more of the milestone events outlined in step A, step B and step C in the table contained in Clause 8.2, GSK shall pay to Immutep such missed milestone payment at such time as the subsequent milestone event occurs.

  

	 	8.4	 Royalty Payments to Immutep. As a further
consideration for the licences granted by Immutep to GSK under Clause 2, GSK shall pay to Immutep royalties on annual Net Sales of the Licensed Product during a Calendar Year, on a Licensed Product-
by-Licensed Product and country-by-country basis at the following rates, in accordance with and subject to the provisions of this
Clause 8.4 and Clauses 8.5 through Clause 8.17: 

  

			
		
	 [***]  
	  	[***]
		
	 [***]  
	  	[***]
		
	 [***]  
	  	[***]

  

	 	8.4.1	 [***]. 

  

	 	8.4.2	 [***]. 

  

	 	8.5	 Royalty Term. GSK’s obligation to pay royalties with respect to a
Licensed Product will continue on a country-by-country and Licensed Product-by-Licensed
Product basis from the First Commercial Sale of the Licensed Product in that country until [***]. 

  
 23 

					
	Confidential	  		  	Execution Copy

  

	 	8.6	 Know-How Royalty. In those countries
of the Territory in which there is no Valid Claim within the Immutep Background Patents, Merck-Serono Patents or Collaboration Patents owned or jointly owned or Controlled by Immutep which claims the composition of matter or method of use of the
Licensed Product sold in such country, but Immutep possesses Know-How, including Merck-Serono Know- How necessary to enable GSK to research and develop the Monoclonal Antibody and/or the Licensed Product as
contemplated under this Agreement, then GSK shall pay to Immutep a royalty which shall be reduced by [***] from the royalties agreed pursuant to Clause 8.4 which would be payable if there was a Valid Claim which claims the composition of matter or
method of use of the Licensed Product sold provided that such royalty shall only be payable for [***] from the date of First Commercial Sale on a country-by-country
basis. 

  

	 	8.7	 Royalty on Pending Claims. In those countries of the Territory in which
there is no Valid Claim within the Immutep Background Patents or the Collaboration Patents which claims the composition of matter or method of use of the Licensed Product sold in such country, but any pending patent application has been maintained
no more than: 

  

	 	8.7.1	 [***] from the date of filing of the earliest priority patent application to which such pending patent
application is entitled, in the case of Immutep Background IP, or 

  

	 	8.7.2	 [***] from the date of filing of the earliest priority patent application to which such pending patent
application is entitled, in the case of the Collaboration IP, 

  

	 	 	 and such pending application issues before the end of the periods specified in Clause 8.7.1 or Clause 8.7.2
respectively, claiming the composition of matter or method of use of the Licensed Product sold in such country, GSK shall pay to Immutep an amount equal to the additional [***] of amounts due as set forth in Clause 8.4 in accordance with Clause 8.5,
to the amount already paid to Immutep under Clause 8.6, that would have otherwise been due as if such pending application had been issued at the time of the First Commercial Sale of the Licensed Product in such countries. If a claim in such pending
application does not issue during the periods specified in Clause 8.7.1 or Clause 8.7.2 respectively, this shall not affect the royalty rates payable by GSK to Immutep for such Licensed Product in such country pursuant to Clause 8.6. Should a claim
in such pending application issue after the period specified in Clause 8.7.1 or Clause 8.7.2 respectively, GSK shall pay to Immutep, from the date of issue, the amounts due as set forth in Clause 8.4 in accordance with Clause 8.5.

  

	 	8.8	 Third Party Intellectual Property. On a country-by-country basis, if GSK obtains a licence under any Patent covering in whole or in part any invention wholly or partly claimed by the Monoclonal Antibody Patents
which would, in the absence of such licence, be infringed by GSK’s activities under this Agreement, GSK shall: 

  

	 	8.8.1	 Be entitled to offset [***] of the royalties in any Calendar Quarter paid to such Third Parties against the
royalties due to Immutep under Clause 8.4 or Clause 8.7. 

  

	 	8.8.2	 In the event that the royalties paid to any such Third Party in a Calendar Quarter pursuant to this Clause 8.8
exceeds the amount by which GSK may credit and offset its payments to Immutep in a Calendar Quarter, GSK shall be entitled to carry forward the excess to offset royalties due to Immutep in any future Calendar Quarter. 

  
 24 

					
	Confidential	  		  	Execution Copy

  

	 	8.8.3	 The right to offset against the royalties due to Immutep (pursuant to Clause 8.4 or Clause 8.7) contained in
this Clause 8.8 shall apply in respect of any right or rights GSK obtains pursuant to the INSERM Agreement and/or the Merck-Serono Agreement, whether on account of Immutep’s insolvency, liquidation or otherwise (including but not limited to the
transfer of the rights and obligations under the INSERM Agreement and/or the Merck- Serono Agreement to GSK). 

  

	 	8.9	 Minimum Royalty Payment to Immutep.

  

	 	8.9.1	 Nothing contained in Clause 8.6, Clause 8.7, Clause 8.8.1 and Clause 8.8.2 shall have the effect of reducing
the royalties paid to Immutep under Clause 8.4 to less than [***] of the royalty payment under Clause 8.4 on annual, country-by-country, aggregate Net Sales of the
Licensed Product. For clarity, this restriction shall not affect the operation of Clause 8.8.3 which may have the effect of reducing the royalties paid to Immutep under Clause 8.4 to less than [***] to the extent and to the level of the additional
costs GSK is required to incur in becoming a direct licensee under the INSERM Agreement and the Merck-Serono Agreement. For further clarity, the effect of any royalty reduction pursuant to this Clause 8.9 shall not result in any additional payment
from Immutep to GSK. 

  

	 	8.10	 Disagreement regarding Valid Claim and
other Patent matters. In the event there is any disagreement between the Parties under this Clause 8 as to whether any Valid Claim covers any composition of matter or method of use or otherwise covers
any Licensed Product pursuant to Clause 8.4, Clause 8.5, Clause 8.6 and/or Clause 8.7, or as to whether any Valid Claim covers any invention claimed by the Monoclonal Antibody Patents pursuant to Clause 8.8, the Parties shall attempt to resolve such
dispute first through the JPS which shall endeavour in good faith to resolve this and all other Patent matters under its authority in the first instance, and then, if the JPS cannot agree, then via the process of escalation as provided in Clause
10.1 (with the exception that GSK shall not have the deciding vote in respect of matters raised under this Clause 8.10). In the event that the Senior IP Representatives cannot agree a resolution to the disagreement, then the parties shall proceed to
dispute resolution pursuant to Clause 18. 

  

	 	8.11	 Commencement of Royalty Payments. 

 

	 	8.11.1	 Beginning with the Calendar Quarter in which the First Commercial Sale occurs for a Licensed Product and for
each Calendar Quarter thereafter, royalties shall be payable by GSK to Immutep pursuant to this Clause 8.11.1 within [***] following the end of each such Calendar Quarter. Each royalty payment shall be accompanied by a report (the
“Payment Report”) in respect of the preceeding Calendar Quarter summarizing the number, description and aggregate Net Sales of such Licensed Product sold during such Calendar Quarter on a
country-by- country basis in British Pounds Sterling and the calculation of royalties due. Notwithstanding the foregoing, once a First Commercial Sale has occurred, in the event that no royalties are payable
in respect of a given Calendar Quarter, GSK shall submit a royalty report so indicating. 

  

	 	8.11.2	 Beginning with the Calendar Year in which the First Commercial Sale occurs for a Licensed Product and for each
Calendar Year thereafter, in respect of the preceeding Calendar Year, solely for the five (5) countries with the highest level of Net Sales, a statement of deductions applied to determine Net Sales for such five (5) countries shall be
provided to Immutep pursuant to this Clause 8.11.2 within [***] following the end of each such Calendar Year. 

  
 25 

					
	Confidential	  		  	Execution Copy

  

	 	8.12	 Currency and Timing of Payments.
All payments due to Immutep under this Agreement shall be made in British Pounds Sterling, subject to Clause 8.12.2, within the relevant period, or if no period is stipulated, within [***] after receipt of the relevant Invoice.

  

	 	8.12.1	 In the event that GSK receives payment in respect of Net Sales in a currency other than British Pounds
Sterling, the relevant royalties payable shall be calculated in British Pounds Sterling at the rate of exchange in line with the method utilised for calculating exchange rates by GSK’s group reporting system and published accounts, in which
cumulative year-to-date average rates are calculated as the average of the preceding 31st of December spot rate plus the closing spot rates of each of the relevant
months to the date at the end of the period for which the calculation is applicable. For clarity, the following example illustrates such a calculation: The cumulative average rate for the five (5) months to May would be computed by taking the
sum of the spot rates of the preceding 31st of December, plus the month-end spot rates for each of the five (5) months to May, and divided the sum by six (6). For further clarity, at the Effective Date,
GSK current group reporting system utilises rates of exchange quoted by Reuters. 

  

	 	8.12.2	 Upon Immutep’s request, not withstanding anything else in this Clause 8.12, upon making any payment that
is due under this Agreement to Immutep, GSK shall transfer the British Pounds Sterling equivalent amount of the amount payable to Immutep in Euros, utilising the current spot rate GSK is able to obtain on the open market, from British Pounds
Sterling to Euros and net of any conversion fees or charges (should any such conversion fees or charges be applicable). 

  

	 	8.12.3	 All payments shall be made by electronic wire transfer of immediately available funds directly to an account of
Immutep as designated by them or to any other account which Immutep may specify by written notice. 

  

	 	8.13	 Late Payments. If any payment due by one Party to another Party pursuant to this Agreement is overdue
then such Party shall pay interest thereon (before and after any judgment) at an annual rate (but with interest accruing on a daily basis) of [***] on the due date of payment (or on the next Business Day if the due date is not a Business Day), such
interest to be pro-rated for the number of days from the date upon which payment of such sum became due until payment thereof in full together with such interest; provided, however, that in no event shall such
rate exceed the maximum legal annual interest rate. The payment of such interest shall not limit a Party from exercising any other rights it may have as a consequence of the lateness of any payment. Interest shall be payable except in the following
circumstances: 

  

	 	8.13.1	 where payments are disputed or are pending resolution; and/or 

 

	 	8.13.2	 where the payment has been delayed by a Party due payment (for instance due to invalid or late changes to bank
details, non-compliant invoices, etc). 

  

	 	8.14	 Records Retention. Commencing with the First Commercial Sale of a Licensed Product in the Territory, GSK
shall keep complete and accurate records of Net Sales for a period of [***] after the year in which such sales occurred, such records to be in sufficient detail to permit Immutep to confirm the completeness and accuracy of the information presented
in each Payment Report. 

  
 26 

					
	Confidential	  		  	Execution Copy

  

	 	8.15	 Audits. For a period of [***] after the year in which such sales of a Licensed Product occurred, at the
request and expense of Immutep, GSK shall permit an independent, certified public accountant of nationally recognized standing appointed by Immutep, and reasonably acceptable to GSK, at reasonable times and upon [***] notice, but in no case more
than once [***], to examine such records as may be necessary for the sole purpose of verifying the calculation and reporting of Net Sales and the correctness of any royalty payments made under this Agreement for any period within the preceding
[***]. The independent, certified public accountant shall disclose to Immutep only the royalty amounts relating to the Net Sales of the Licensed Product, which it believes to be due and payable under this Agreement to Immutep and shall disclose no
other information revealed in such audit however, for the sole purpose of complying with its obligations under the Merck-Serono Agreement, nothing in this Clause 8.15 shall prevent Immutep from receiving a fully detailed audited report from such
certified public accountant and from disclosing such report. Any and all records examined by such independent, certified public accountant shall be deemed GSK’s Confidential Information which may not be disclosed by said independent, certified
public accountant to any other person (including Immutep), except in accordance with this Clause 8.15. If, as a result of any inspection of the books and records of GSK, it is shown that a payment to Immutep under this Agreement was less than the
amount which should have been paid, then GSK shall make all payments required to be made to eliminate the discrepancy within [***]. Immutep shall pay for such audit, except that, in the event that the audit found a royalty payment to be at least
[***] less than the amounts that should have been paid during the year in question, GSK shall pay the reasonable costs of the audit. 

  

	 	8.16	 VAT and Indirect Taxes. All sums payable by GSK hereunder are exclusive of any sales, value added taxes
and other applicable indirect taxes or duties. The Parties agree that, where appropriate, the Parties shall provide each other with a valid tax invoice, and against the production of such invoice, the Parties shall pay the amount of any such tax to
the other Party. Should such amounts of tax be refunded subsequently by the fiscal authorities, the Party receiving the refund shall immediately notify the other Party and refund these monies within [***] of receipt. 

 

	 	8.17	 Tax Withholding. Any tax paid or required to be withheld by GSK for the
benefit of Immutep on account of any payments payable to Immutep under this Agreement shall be deducted from the amount of any payments otherwise due. GSK shall secure and send to Immutep proof of any such taxes withheld and paid by GSK for the
benefit of Immutep, and shall, at Immutep’s request, provide reasonable assistance to Immutep in recovering such taxes. Immutep warrants that it is resident for tax purposes in France and that it is entitled to relief from United Kingdom income
tax under the terms of the double tax agreement between the United Kingdom and France. Immutep shall notify GSK immediately in writing in the event that Immutep ceases to be entitled to such relief. Pending receipt of formal certification from the
United Kingdom Inland Revenue, GSK may pay royalty income and any other payments under this Agreement to Immutep by deducting tax at a rate specified in the double tax treaty between the United Kingdom and France Immutep agrees to indemnify and hold
harmless GSK against any loss, damage, expense or liability arising in any way from a breach of the above warranties or any future claim by a United Kingdom tax authority or other similar body alleging that GSK was not entitled to deduct withholding
tax on such payments at source at the treaty rate. 

  

	 	8.18	 No Further Payments. GSK shall not be required to make any
further payments to Immutep or Third Parties except as expressly provided for under this Agreement. 

  
 27 

					
	Confidential	  		  	Execution Copy

  

	 	8.19	 Payments Made by Affiliates. Immutep agrees that any payment that GSK is required to make under this
Agreement may be paid by either GSK or any of its Affiliates, as GSK may so determine. 

 9 OWNERSHIP OF INTELLECTUAL PROPERTY AND
PATENT RIGHTS 
  

	 	9.1	 Excluded Intellectual Property. Except for those rights expressly granted under or pursuant to the
provisions of this Agreement, nothing herein shall be construed as creating, granting or conveying to one Party any licence, right, title or other interest in or to any Intellectual Property owned or Controlled by the other Party or its Affiliates:
(i) existing prior to the Effective Date; or (ii) independently discovered and developed during the Term of this Agreement by such other Party or its Affiliates other than in performance of its obligations under this Agreement and without
use of such other Party’s Intellectual Property or other Confidential Information. 

  

	 	9.2	 GSK Programme Intellectual Property. GSK shall have exclusive ownership of any GSK Programme IP. Immutep
hereby irrevocably and unconditionally waives any present or future right, claim and/or interest to any Intelletual Property invented pursuant to this Agreement independently of the Research Collaboration. 

 

	 	9.3	 Arising Intellectual Property from the Research Programme. 

 

	 	9.3.1	 Ownership of all right, title and interest in any Intellectual Property which is invented in the performance of
the Research Programme shall be determined as follows: 

  

	 	(a)	 Immutep shall have exclusive ownership of any Immutep Non-Licensed
Arising IP; 

  

	 	(b)	 Immutep shall have exclusive ownership of any Immutep Licensed Arising IP; 

 

	 	(c)	 GSK shall have exclusive ownership of any GSK Non-Licensed Arising IP;

  

	 	(d)	 Ownership of any Intellectual Property which is invented solely by GSK during the Research Programme, which has
arisen directly from the use of the Merck-Serono IP shall vest exclusively in Immutep provided however, that this right shall then be subject to GSK’s further rights under Clause 9.4 (“GSK Licensed Arising
IP”); 

  

	 	(e)	 Immutep and GSK shall jointly own any Joint Non-Licensed Arising IP;

  

	 	(f)	 Ownership of any Intellectual Property which is invented during the Research Programme which has arisen
directly from the use of the Merck- Serono IP, and which is not separable into either Immutep Licensed Arising IP or GSK Licensed Arising IP (for patent applications, to the extent that a single claim spans subject matter falling under both Immutep
Licensed Arising IP or GSK Licensed Arising IP) shall vest exclusively in Immutep: provided however, that this right shall then be subject to GSK’s further rights under Clause 9.4 (“Joint Licensed
Arising IP”); and 

  

	 	(g)	 Ownership of any Intellectual Property arising from the Research Programme shall vest exclusively in Immutep,
provided that the Intellectual Property is conceived by the Research Plan as attached as of the Effective Date as Schedule 1 without further inventive contribution by GSK. 

 

	 	9.4	 Assignment of Immutep Intellectual Property. 

 

	 	9.4.1	 To the extent that any GSK Licensed Arising IP and/or the Joint Licensed Arising IP is capable of prospective
assignment, Immutep now assigns such GSK Licensed Arising IP and a joint interest in the Joint Licensed Arising IP to GSK; and to the extent any GSK Licensed Arising IP and any GSK interest in the Joint Licensed Arising IP cannot be prospectively
assigned, Immutep will immediately assign such GSK Licensed Arising IP and any 

  
 28 

					
	Confidential	  		  	Execution Copy

  

	 	 	 GSK interest in the Joint Licensed Arising IP to GSK as and when such GSK Licensed Arising IP and any GSK
interest in the Joint Licensed Arising IP is created provided however that all such GSK Licensed Arising IP and Immutep’s joint interest in the Joint Licensed Arising IP assigned to GSK shall continue to be deemed “Collaboration
Patents” for the purpose of Clause 8.5. 

  

	 	9.5	 Inventorship; Divisional Patent applications. Inventorship shall be determined for the purposes of this
Agreement on a claim-by-claim basis in accordance with the patent laws applicable in the USA. In the event that a Patent contains claims that are jointly invented and
claims that are invented solely by one Party or it would otherwise be desirable to separate claims, then the Parties shall, where it is reasonable and practical to do so, use reasonable endeavours to file one or more divisional applications
separating out the affected claims. 

  

	 	9.6	 Joint Arising Intellectual Property. 

 

	 	9.6.1	 Both Immutep’s right title and interest in the Joint Licensed Arising IP, the Joint Non-Licensed Arising IP and GSK’s right title and interest in the Joint Licensed Arising IP and the Joint Non-Licensed Arising IP shall be subject to the rights and
licences granted in this Agreement and in particular the following Clause 9.6.2 shall apply. 

  

	 	9.6.2	 Subject to any licenses granted hereunder and Clause 7, each Party shall have a
non-exclusive right under the relevant Joint Licensed Arising IP and the Joint Non-Licensed Arising IP to exploit compounds and/or products that are not, or do not
include, the Monoclonal Antibody or Licensed Product and neither Party shall have any obligation to account to the other for profits, or to obtain any approval of the other Party to license, assign, mortgage or exploit Joint Licensed Arising IP and
the Joint Non-Licensed Arising IP by reason of joint ownership, and may otherwise undertake all activities a sole owner might undertake with respect to such Joint Licensed Arising IP and the Joint Non-Licensed Arising IP without the consent of and without accounting to the other joint owner, except as otherwise provided in this Agreement, or as the Parties may otherwise agree in writing.

  

	 	9.7	 Patent Term Extension. GSK shall control the filing of any
application for patent term extension or supplementary protection certificate relating to a Licensed Product in the Territory and Immutep shall agree to cooperate and provide input in the filing for applications and to do all such acts, provide and
sign all documents or copies thereof which may be reasonably necessary or desirable for the filing of any application for patent term extension relating to a Licensed Product in the Territory. For clarity, GSK shall at all times, in fulfilling its
obligations under this Clause 9.7, use its sound commercial judgment with regard to the Licensed Product. 

 10 MANAGEMENT OF PATENT
RIGHTS 
  

	 	10.1	 Prosecution, Maintenance and Defence of Managed Patents. GSK shall be responsible for, and undertake,
the preparation, filing, prosecution, maintenance and extension of Managed Patents. GSK shall bear the worldwide Patent Costs incurred in relation to the Managed Patents. GSK shall, in a timely manner via the JPS, solicit Immutep’s advice and
review of the nature and text of any Managed Patent and prosecution matters related thereto, including any correspondence between GSK and any government Intellectual Property or Patent authorities, agencies or other government bodies, in reasonably
sufficient time prior to filing thereof. In the event that the JPS members are unable to agree on any matter relating to the filing, prosecution or maintenance of any Managed Patent, the JPS members shall, by 

  
 29 

					
	Confidential	  		  	Execution Copy

  

	 	 	 written notice to the other, refer such matter to such senior representative with responsibility for
intellectual property matters as designated by Immutep from time to time, and a senior representative of GSK Global Patents, or such other person designated by GSK from time to time (collectively, the “Senior IP Representatives”),
for resolution. The Senior IP Representatives shall meet promptly to discuss the matter submitted and to determine a resolution. If the Senior IP Representatives are unable to determine a resolution in a timely manner, which shall in no case be more
than [***] after the matter was referred to them, then GSK shall have the deciding vote on the matter. For clarity, GSK shall at all times, in fulfilling its obligations under this Clause 10.1, use its sound commercial judgment with regard to the
Licensed Product. 

  

	 	 	 If a decision is made, prior or subsequent to filing any Managed Patent anywhere in the world, not to file,
prosecute or maintain or to significantly reduce the scope of such Managed Patent or claims encompassed by such Managed Patent in any country of the world or Territory, as the case may be, GSK shall give Immutep notice thereof within a reasonable
period prior to allowing such Managed Patent or such claims encompassed by such Managed Patent to reduce (the scope of such Managed Patent claims), permit such Managed Patent to lapse or become abandoned or unenforceable, and Immutep shall
thereafter have the right, at its sole expense and in its own name, to prepare, file, prosecute and maintain such Managed Patent or claims encompassed by such Managed Patent in such country provided that Immutep grants to GSK a non-exclusive, subject to royalty payment under Clause 8.4 of this Agreement, worldwide licence under such Managed Patent assumed by Immutep, as soon as it has been assumed by Immutep. For the avoidance of doubt, no
breach nor breaches of this Clause 10.1 shall give rise to a right to terminate this Agreement unless the breaches are material, occur persistently over a significant period of time and cause significant loss of the scope of Patent protection.

  

	 	10.2	 Prosecution, Maintenance and Defence
of GSK Arising Patents. GSK shall have the sole right, at its cost, to prepare, file, prosecute, maintain and extend GSK Arising Patents throughout the world. To the extent that any such
Patent claims subject matter that arose in the performance of the Research Programme, GSK shall in a timely manner solicit Immutep’s advice and review of the nature and text of any such Patent in reasonably sufficient time prior to filing
thereof, and GSK shall give due consideration to Immutep’s comments related thereto. For the avoidance of doubt, no breach nor breaches of this Clause 10.2 shall give rise to a right to terminate this Agreement or any Research Program unless
the breaches are material, occur persistently over a significant period of time and cause significant loss of the scope of Patent protection. 

  

	 	10.3	 Patent Listing. GSK shall be responsible for performing all patent listing acts and
requirements for any Licensed Product with respect to which GSK has the exclusive rights pursuant to Clause 2 to develop and commercialize, and that have become the subject of a Marketing Authorisation Application submitted to any applicable
Regulatory Authority, such acts and requirements to include all so-called “Orange Book” listings required under the Hatch-Waxman Act, all so called “Patent Register” listings as required in
Canada, all listings and other acts required of the reference product sponsor under the Biologicals Price Competition and Innovation Act of 2009 (42 USC 262), or any foreign equivalents thereof. Prior to such listings, the Parties will meet, through
the JPS, to evaluate and identify all applicable Patents, and GSK shall have the right to review, where reasonable, original records relating to any invention for which Patents are being considered by the JPS for any such listing. Notwithstanding
the preceding sentence, GSK will retain final decision-making authority as to the listing of all applicable Patents for such Licensed Product and all 

  
 30 

					
	Confidential	  		  	Execution Copy

  

	 	 	 other acts pertaining to such patent listings as required by law, statue or regulation, regardless of which
Party owns such Patent Right, and any such final decision made in good-faith on the matter shall not be subject to any further review under Clause 18 or otherwise under this Agreement. For the avoidance of doubt, any decision made by GSK under this
Clause 10.3 shall not be used to determine, as between the Parties, whether a Patent contains any Valid Claim or whether any Licensed Product is covered by any Valid Claim within the Immutep Background IP or Collaboration IP. 

 

	 	10.4	 Notification. Each Party shall promptly provide written notice to the other Party during
the Term of any of the following: 

  

	 	10.4.1	 any known infringement or suspected infringement by a Third Party of any Immutep Background IP or Collaboration
IP; 

  

	 	10.4.2	 any certification received under the Hatch-Waxman Act (i.e., a Paragraph IV Certification under 21 U.S.C.
Section 355 and 21 C.F.R. Part 314) or any foreign equivalents with respect to the Licensed Product(s) and/or in relation to any Immutep Background IP or Collaboration IP; 

 

	 	10.4.3	 any application submitted by a subsection (k) applicant under the Biologicals Price Competition and
Innovation Act of 2009 (42 USC 262) or any foreign equivalents with respect to the Licensed Product and/or in relation to any Immutep Background IP or Collaboration IP; 

 

	 	10.4.4	 any patent-related challenge, such as opposition, interference, re- examination,
re-issue, revocation, non-entitlement, invalidity or unenforceability, commenced by a Third Party in respect of any Immutep Background IP or Collaboration IP;

  

	 	10.4.5	 any misappropriation or misuse by a Third Party of Immutep Background IP or Collaboration IP.

  

	 	10.5	 Infringement in Territory. In respect of the Immutep
Intellectual Property licensed to GSK pursuant to Clause 2, the Joint Licensed Arising IP and the Joint Non- Licensed Arising IP GSK shall have the initial right, but not the obligation, using counsel of its choice at its own cost to bring suit
under, or to defend against, as appropriate, the matters listed in Clause 10.4 above to the extent such matters affect GSK’s licensed rights hereunder. GSK shall have sole control of any decisions or other aspects of such action (including any
settlement), subject to this Clause 10.5 and Clause 10.6, and Immutep shall, upon request, give to GSK such reasonable assistance as GSK may reasonably request, including by signing or executing any necessary documents and consenting to its name
being used in the proceedings; provided that GSK shall reimburse Immutep for any reasonable out-of-pocket expenses incurred while providing such assistance. GSK shall
keep Immutep reasonably informed of the progress of the action and shall consider the comments and observations of Immutep in prosecuting the action. If GSK does not institute any such action within [***] of a notice from Immutep requiring
confirmation from GSK of whether action will be taken (or such shorter period where there is an earlier deadline for taking action), then Immutep shall have the right, but not the obligation, at its own cost, to commence proceedings regarding such
matter. Immutep shall, subject to this Clause 10.5 and Clause 10.6, have sole control of any decisions or other aspects of the action (including any settlement) and GSK shall, upon request, give to Immutep such reasonable assistance as Immutep may
reasonably request provided that Immutep shall reimburse GSK for any reasonable out-of-pocket expenses incurred while providing such assistance and that nothing in this
Clause 10.5 shall oblige GSK to lend its name to, or be joined in, any proceedings commenced by Immutep pursuant to the foregoing. 

  
 31 

					
	Confidential	  		  	Execution Copy

  

	 	10.6	 Settlement. Neither GSK nor Immutep shall, without the prior written consent of the other
Party, make any admission or enter into a settlement, consent to judgement or other voluntary final disposition in connection with any such proceedings under this Clause 10 that: (i) extends, or purports to extend, the settling Party’s
rights under the Immutep Background IP or Collaboration IP beyond the rights granted pursuant to this Agreement; (ii) makes any admission regarding wrongdoing or inequitable conduct by the other Party, its Affiliates or Sub-licensees; (iii) makes any admission regarding the invalidity, unenforceability, scope of claims or absence of infringement of any Patent owned by the other Party or regarding the existence or relevance of
any prior art relating to any such Patent; (iv) subjects the other Party to an injunction or other equitable relief; or (v) obligates the other Party to make a monetary payment; (vi) puts the other Party in breach of any contractual
commitment to a Third Party which has been disclosed to the settling Party; (vii) except to the extent permitted under Clauses 10.1 to 10.4, results in the amendment of any Immutep Background IP or Collaboration IP; (viii) except to the
extent permitted under Clauses 10.1 to 10.4, diminishes the other Party’s right, title or other ownership interest in or to the Immutep Background IP or the Collaboration IP; or (ix) surrenders subject matter or dedicates any subject
matter to the public in respect of any Patent owned by the other Party, in all cases without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed. 

 

	 	10.7	 Recovery. Any damages or award (including any award of costs) made in the proceedings shall first be
applied to the reimbursement of the legal costs of GSK (and of Immutep if Immutep has participated in or has taken over the conduct of the proceedings). Any excess amounts shall be treated as follows: (i) if GSK has taken over the conduct of
the proceedings, then such excess amounts shall be treated as Net Sales; or (ii) if Immutep has taken over conduct of the proceedings, then such excess amounts shall be equally shared between GSK and Immutep. 

 

	 	10.8	 Trademarks. GSK shall be responsible for the selection of all trademarks which it employs in connection
with the Licensed Product in the Territory and shall own and control such trademarks. GSK shall be responsible for registration and maintenance of all such trademarks. Nothing in this Agreement shall be construed as a grant of rights, by licence or
otherwise, to Immutep to use such trademarks or any other trademarks owned by GSK for any purpose. GSK shall own such trademarks and shall retain such ownership upon termination or expiration of this Agreement. 

11 REGULATORY & PHARMACOVIGILANCE 
  

	 	11.1	 Pharmacovigilance. GSK shall be responsible for the timely reporting of product quality complaints,
adverse events and product safety data related to the Monoclonal Antibody and Licensed Product to the appropriate Regulatory Agency or other health authorities. GSK shall maintain a global adverse event database for the Monoclonal Antibody and
Licensed Product. GSK shall respond effectively in a timely manner to all safety issues with respect to the Monoclonal Antibody and Licensed Product, and to all requests made by any Regulatory Authority in the Territory. 

 

	 	11.2	 Ownership of Regulatory Filings. GSK shall own and maintain all regulatory filings for the Monoclonal
Antibody and the Licensed Product filed pursuant to this Agreement, including all INDs. 

 12 CONFIDENTIALITY 

 

	 	12.1	 Confidentiality; Exceptions. Except to the extent expressly authorized by this Agreement or otherwise
agreed in writing, the Parties agree that, during the Term and for a period of [***] thereafter, the receiving Party (the “Receiving Party”) shall keep confidential and shall not publish or otherwise disclose or use for any purpose
other than as provided for in this Agreement any confidential and 

  
 32 

					
	Confidential	  		  	Execution Copy

  

	 	 	 proprietary information and materials, patentable or otherwise (including, this Agreement, trade secrets, Know-How, inventions or discoveries, formulae, methods, materials, processes, techniques and information relating to a Party’s past, present and future marketing, financial, and research and development
activities of any product or potential product or useful technology of the Disclosing Party and the pricing thereof) (collectively, “Confidential Information”), in any form (written, oral, photographic, electronic, magnetic, or
otherwise), which is disclosed or made available to it by the other Party (the “Disclosing Party”) or otherwise received or accessed by a Receiving Party in the course of performing its obligations or exercising its rights under
this Agreement, except to the extent that it can be established by the Receiving Party that such Confidential Information: 

  

	 	12.1.1	 was in the lawful knowledge and possession of the Receiving Party prior to the time it was disclosed or made
available to, or learned by, the Receiving Party, or was otherwise developed independently by the Receiving Party without reference to or use of the Disclosing Party’s Confidential Information, as evidenced by written records kept in the
ordinary course of business or other documentary proof of actual use by the Receiving Party; 

  

	 	12.1.2	 was available to the public generally or otherwise part of the public domain at the time of its disclosure to
the Receiving Party; 

  

	 	12.1.3	 became available to the public generally or otherwise part of the public domain after its disclosure and other
than through any act or omission of the Receiving Party; 

  

	 	12.1.4	 was disclosed to the Receiving Party, other than under an obligation of confidentiality to or at the direction
of the Disclosing Party, by a Third Party who had no obligation not to disclose such information to others; 

  

	 	12.1.5	 where the Disclosing Party provides its consent, which shall not be unreasonably withheld;

  

	 	12.1.6	 where such Confidential Information is covered by the obligations Immutep owes to Ares Trading SA in accordance
with the Merck-Serono Agreement, and Immutep is required to disclose to Ares Trading SA, provided that Immutep shall procure that Ares Trading SA shall maintain the Confidential Information in accordance with the provisions of this Clause 12 for the
Term of this Agreement; or 

  

	 	12.1.7	 where such Confidential Information of Immutep is required to be disclosed in accordance with this Agreement.

  

	 	12.2	 Press Release; Disclosure of Agreement. Promptly after the Effective Date, either or both Parties may
issue mutually agreed public announcements of the execution of this Agreement, and either Party may make subsequent public disclosure of the content of such press release in the same context without further approval of the other Party. Neither Party
shall be free to issue any other press release or similar public announcement regarding the Agreement or its subject matter (it being understood that publication in scientific journals, presentation at scientific conferences and meetings and the
like are intended to be covered by Clause 12.3 and not subject to this Clause 12.2), except with the other Party’s consent as may be required under this Agreement, further except that GSK shall be permitted to make subsequent public disclosures
provided it has informed Immutep of the content of such disclosure in advance of such planned disclosure date. The principles to be observed by Immutep and GSK in any such permitted public disclosures with respect to this Agreement or its subject
matter shall be: accuracy, the requirements of confidentiality under this Clause 12, and the normal business practice in the pharmaceutical industry for disclosures by companies of comparable size and comparable regulatory requirements to GSK and
Immutep, respectively. 

  
 33 

					
	Confidential	  		  	Execution Copy

  

	 	12.3	 Publications. 

 

	 	12.3.1	 Publications by Immutep. During the Term, Immutep may publish or
present data or results that it generates in the performance of the Research Programme in scientific journals or conferences, subject to the prior review and comment by GSK, as follows: Immutep shall provide GSK with the opportunity to review any
such proposed abstract, manuscript or presentation by delivering a copy thereof to GSK no less than thirty (30) days before its intended submission for publication or presentation. GSK shall have [***] from its receipt of any such abstract,
manuscript or presentation in which to notify Immutep in writing of any specific objections to the disclosure of Confidential Information of either Party. In the event GSK objects to the disclosure in writing within such [***] period:

  

	 	(a)	 Immutep shall not submit the publication or abstract or make the presentation containing the objected-to information until the Parties have agreed to such content; 

  

	 	(b)	 Immutep shall delete from the proposed disclosure any Confidential Information of GSK upon the request of GSK;
and 

  

	 	(c)	 if GSK determines that such abstract, manuscript or presentation contains patentable subject matter which would
be either Immutep Background IP or Collaboration IP, Immutep shall delay such publication for up to an additional [***] to enable the pursuit of appropriate Patent protection. Once any such abstract or manuscript is accepted for publication, Immutep
will provide GSK with a copy of the final version of the manuscript or abstract. 

  

	 	12.3.2	 Publications by GSK. GSK may publish or present data or results
including but not limited to abstracts, manuscripts or presentations, relating to the Monoclonal Antibody and/or the Licensed Product in scientific journals or at scientific conferences. In the event GSK wishes to publish or present results
utilising the Immutep Licensed Arising IP, Joint Licensed Arising IP and the GSK Licensed Arising IP, GSK shall provide a copy of the proposed written publication or an outline of a proposed oral disclosure at least [***] prior to submission for
publication or presentation. For clarity, Immutep shall not have the right to comment, contribute or affect in any way the aforementioned abstracts, manuscripts or presentions, relating to the Monoclonal Antibody and/or the Licensed Product
published or presented by GSK. 

  

	 	12.3.3	 General. Notwithstanding Clauses 12.3.1 and 12.3.2, once an abstract, manuscript or
presentation has been reviewed by a Party in accordance with Clause 12.3, the same content included in such abstract, manuscript or presentation does not have to be provided again to the other Party for review for a later submission for publication,
except if there is any change at all to the proposed disclosure, in which case, the prior review of the other Party shall be required. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly
recognized, and co- authorship shall be determined in accordance with customary standards. Furthermore, with respect to any proposed abstracts, manuscripts or summaries of presentations by investigators or other Third Parties having the right to do
so, such materials shall be subject to review under this Clause 12.3 to the extent that GSK or Immutep (as the case may be) has the right to do so. 

  
 34 

					
	Confidential	  		  	Execution Copy

  

	 	12.4	 Remedies. Each Party shall be entitled to seek, in addition to any other right or remedy it may have at
law or in equity, a temporary injunction, without the posting of any bond or other security, enjoining or restraining the other Party from any violation or threatened violation of this Clause 12. 

 

	 	12.5	 Use of Name. Neither GSK nor its Affiliates, nor its Sub-licensees shall use the “INSERM” name or “ARES Trading SA” name or the name of their Affiliates, in any publicity or advertising without the prior written consent of INSERM or ARES Trading
SA, except where required under the terms of this Agreement. This provision shall not prevent GSK nor its Affiliates, nor its Sub-licensees from any disclosure under this Clause 12.5 as required by applicable
law. 

 13 REPRESENTATIONS AND WARRANTIES 
  

	 	13.1	 Representations and Warranties of Both Parties. Each Party hereby represents and warrants to the other
Party, as of the Effective Date, that: 

  

	 	13.1.1	 such Party is duly organized, validly existing and in good standing under the laws of the jurisdiction of its
incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions of this Agreement; 

  

	 	13.1.2	 such Party has taken all necessary action on its part to authorize the execution and delivery of this Agreement
and the performance of all of its obligations under this Agreement; 

  

	 	13.1.3	 this Agreement has been duly executed and delivered on behalf of such Party and constitutes its legal, valid
and binding obligation, enforceable against it in accordance with the terms of this Agreement (subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, to judicial principles
affecting the availability of specific performance and to general principles of equity, whether enforceability is considered a proceeding at law or equity); 

  

	 	13.1.4	 the execution, delivery and performance of this Agreement or the grant of any rights or licenses by such Party
to the other Party does not conflict with and is not inconsistent with the terms or conditions of any agreement, instrument or understanding, oral or written, to which it is a Party or by which it is bound; or violate any law or regulation of any
court, governmental body or administrative or other agency having jurisdiction over such Party; 

  

	 	13.1.5	 no government authorization, consent, approval, license, exemption of or filing or registration with any court
or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable laws, rules or regulations currently in effect, is or will be necessary for, or in connection with, the transaction
contemplated by this Agreement, or for the performance by it of its obligations under this Agreement; and 

  

	 	13.1.6	 it has not, to its knowledge, employed or used a contractor or consultant that has employed any individual or
entity debarred by the FDA (or subject to a similar sanction of EMA) or, to its knowledge, any individual who or entity which is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMA), in the conduct of the
research and development of the Monoclonal Antibody as of the Effective Date. 

  

	 	13.2	 Representations and Warranties of Immutep. Immutep hereby represents and warrants to GSK, as of the
Effective Date, that: 

  

	 	 	 [***]. 

  
 35 

					
	Confidential	  		  	Execution Copy

  

	 	13.3	 Immutep Covenants. Immutep hereby covenants to GSK that: 

 

	 	13.3.1	 all employees, consultants and agents of Immutep or its Affiliates working in or otherwise involved in the
Research Programme, or otherwise in relation to the Monoclonal Antibody, shall be under the obligation to assign all right, title and interest in and to their inventions conceived and discoveries made within the scope of their employment, whether or
not patentable, if any, to Immutep as the sole owner thereof; 

  

	 	13.3.2	 Immutep shall at all times perform its activities pursuant to this Agreement in compliance in all material
respects with good laboratory and clinical practices, in each case to the extent customary for any particular activity and as applicable under the laws and regulations of the country and the state and local government wherein such activities are
conducted. 

  

	 	13.3.3	 it shall not during the Term grant to any Third Party (i) any right or licence or (ii) any lien,
mortgage or security interest or any other similar interest that would give the holder the right to convert the interest into ownership, relating to any of the Immutep Background IP or Collaboration IP that would conflict with, restrict or otherwise
limit the scope of any of the rights pertaining to the Monoclonal Antibody. 

  

	 	13.4	 GSK Covenants. GSK hereby covenants to Immutep that; 

 

	 	13.4.1	 all employees, consultants and agents of GSK or its Affiliates working under this Agreement shall be under the
obligation to assign all right, title and interest in and to their inventions conceived and discoveries made within the scope of their employment, whether or not patentable, if any, to GSK as the sole owner thereof; and 

 

	 	13.4.2	 it or its Affiliate, as applicable, shall at all times retain sufficient Control over the GSK Arising IP and
GSK Background IP to be able to grant the licences to Immutep provided for in this Agreement. 

  

	 	13.5	 Compliance with Laws. 

 

	 	13.5.1	 Each Party shall perform its obligations under this Agreement in a manner that complies with all applicable
international, national and local laws in relation to, or otherwise relevant to, its obligations under this Agreement. 

  

	 	13.5.2	 Each Party hereby represents, warrants and covenants that it will not, under any circumstances, and at all
relevant times, make, or cause or authorise 

  
 36 

					
	Confidential	  		  	Execution Copy

  

	 	any third party acting on its behalf to make, directly or indirectly, any prohibited bribes, offers, promises or payments of money, or anything of value, to any official (including but not limited to government
officials, government employees, any political party or political party official, any candidate for political office, or any person otherwise acting in an official capacity) pursuant to all applicable laws (including but not limited to laws
prohibiting bribery or corruption and export control laws, currency exchange laws, customs laws and tax laws), or any other third party, for the purpose of influencing such party’s acts or decisions or in order to obtain or retain business or
secure an unfair business advantage for either party in performing its duties and obligations pursuant to this Agreement. Immutep acknowledges receipt of the ‘Prevention of Corruption – Third Party Guidelines’ as attached at Schedule
2 and agrees to perform its obligations under the Agreement in accordance with the principles set out therein. 

  

	 	13.5.3	 Each Party expressly agrees that this Agreement is the result of arms length negotiations and that neither
Party has entered into this Agreement with a corrupt motive to obtain or retain business or to secure an unfair business advantage. 

  

	 	13.5.4	 Each Party hereby warrants and undertake that they shall at all material times keep and maintain accurate and
up to date accounting records to ensure that all transactions relating to this Agreement are sufficiently documented. 

  

	 	13.6	 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET OUT IN THIS AGREEMENT, NEITHER PARTY MAKES ANY
REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND WITH RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY INCLUDING HEREBY DISCLAIMS ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT
NOT LIMITED TO, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR THAT ANY PATENTS ARE VALID OR ENFORCEABLE OR THAT THEIR EXERCISE DOES NOT OR WILL NOT INFRINGE ANY PATENT RIGHTS OF THIRD PARTIES. 

14 INDEMNIFICATION; INSURANCE 
  

	 	14.1	 Indemnification by GSK. GSK shall indemnify, defend and hold harmless
Immutep and its Affiliates and its and their respective directors, officers, employees and agents, from and against [***]; 

  

	 	14.2	 Indemnification by Immutep. Immutep shall indemnify, defend
and hold harmless GSK, its Affiliates, its Sub-licensees and their respective directors, officers, employees and agents, from and against [***]. 

 

	 	14.3	 Procedure. In the event that either Party or other person entitled to indemnification
under Clause 14.1 or Clause 14.2 (in any case, an “Indemnitee” and, collectively, a Party’s “Indemnitees”) is seeking such indemnification, such Indemnitee shall promptly notify, in writing, the indemnifying
Party of the Third Party Claim as soon as reasonably practicable after such Indemnitee receives notice of such Third Party Claim, such notice to contain a description of the Third Party Claim and the nature and amount of such Loss (to the extent
that the nature and amount of such Loss is known at such time); provided that: 

  

	 	14.3.1	 each Party may provide such notice on its behalf and on behalf of its Indemnitees to the other Party; and

  
 37 

					
	Confidential	  		  	Execution Copy

  

	 	14.3.2	 in the event of a delay in providing such notice, the indemnifying Party shall not be liable for any Losses
that would not have occurred if such notice had been provided promptly. 

  

	 	 	 Each Indemnitee shall thereafter furnish promptly to the indemnifying Party copies of all papers and official
documents received in respect of the Third Party Claim or any Losses and shall permit the indemnifying Party to assume direction and control of the defence of the Third Party Claim (including the sole right to settle it at the sole discretion of the
indemnifying Party, taking into consideration in good faith any reasonable concerns or objections raised by the Indemnitee; provided that such settlement does not impose any obligation on, or otherwise adversely affect, the Indemnitee or other
Party). If the indemnifying Party assumes the defence of a Third Party Claim, except as provided in Clause 14.4, the indemnifying Party shall not be liable to the other Party or any of its Indemnitees for any legal expenses subsequently incurred by
such other Party or Indemnitee(s) in connection with the analysis, defence or settlement of the Third Party Claim. In the event that it is judicially 

  
 38 

					
	Confidential	  		  	Execution Copy

  

	 	 	 determined (in a final, non-appealable decision) or otherwise agreed by
the Parties, that the indemnifying Party is not obligated to indemnify, defend or hold harmless any Indemnitee(s) from and against the Third Party Claim, the other Party shall reimburse the indemnifying Party for any and all actual costs and
expenses (including the reasonable fees of attorneys and other professionals) and any Losses actually paid by the indemnifying Party in its defence of the Third Party Claim with respect to such Indemnitee(s). 

 

	 	14.4	 Participation in Defence. Any Indemnitee seeking indemnity
under this Agreement shall be entitled to participate in, but not control, the defence of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the Indemnitee’s own
expense unless: 

  

	 	14.4.1	 the employment thereof has been specifically authorized by the indemnifying Party in writing;

  

	 	14.4.2	 the indemnifying Party has failed to assume the defence and employ counsel (in which case the other Party shall
control the defence); or 

  

	 	14.4.3	 the named Parties to such Third Party Claim include both the indemnifying Party and the Indemnitee and the
Indemnitee reasonably concludes, that the indemnifying Party and the Indemnitee have conflicting interests that make separate counsel with respect to such Third Party Claim advisable. 

 

	 	14.5	 Cooperation. The Party seeking indemnification shall, and shall cause each of its Indemnitees to:

  

	 	14.5.1	 cooperate as reasonably requested (at the expense of the indemnifying Party) in the defence of the applicable
Third Party Claim; and 

  

	 	14.5.2	 undertake all reasonable steps to mitigate any Losses with respect to such Third Party Claim.

  

	 	14.6	 Insurance. 

  

	 	14.6.1	 Immutep’s Insurance Obligations. Immutep shall maintain or ensure that it is covered by, at its
sole cost, with effect from the Effective Date and during the Term thereafter, adequate insurance against liability and other risks associated with its activities and liabilities contemplated under this Agreement, including but not limited to its
indemnification obligations herein, in such amounts and on such terms as are customary for prudent practices for companies of comparable size to Immutep in the pharmaceutical or biopharmaceutical industry. 

 

	 	14.6.2	 GSK’s Insurance Obligations. GSK hereby represents and warrants to Immutep that it is self-insured
against liability and other risks associated with its activities and obligations under this Agreement in such amounts and on such terms as are customary for prudent practices for global pharmaceutical companies and agrees that it shall remain so
insured throughout the Term. GSK shall furnish to Immutep evidence of such self- insurance, upon request. 

  

	 	14.7	 LIMITATION OF CONSEQUENTIAL DAMAGES. EXCEPT FOR A BREACH OF CLAUSE 12 (CONFIDENTIALITY) OR FOR ANY
CLAIMS OF A THIRD PARTY WHICH ARE SUBJECT TO INDEMNIFICATION UNDER THIS CLAUSE 14, NEITHER IMMUTEP NOR GSK, NOR ANY OF THEIR RESPECTIVE AFFILIATES, SUB-LICENSEES, SUCCESSORS OR ASSIGNEES WILL BE LIABLE TO THE
OTHER PARTY TO THIS AGREEMENT, ITS AFFILIATES OR ANY OF THEIR SUB-LICENSEES FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, RELIANCE, EXEMPLARY OR PUNITIVE DAMAGES OR, LOST DATA OR COST OF PROCUREMENT OF
SUBSTITUTE GOODS OR SERVICES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED
OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE. 

  
 39 

					
	Confidential	  		  	Execution Copy

  

	 	14.8	 LIMITATION. NEITHER GSK NOR IMMUTEP LIMITS OR EXCLUDES ITS LIABILITY FOR FRAUD, FRAUDULENT
CONCEALMENT OR FRAUDULENT MISREPRESENTATION, NOR FOR DEATH OR PERSONAL INJURY ARISING FROM ITS NEGLIGENCE. 

 15 TERM AND TERMINATION

  

	 	15.1	 Term; Expiration. This Agreement shall become effective as of the Effective
Date and, unless earlier terminated pursuant to this Clause 15 or by mutual agreement of the Parties, shall continue in force and effect until [***]. 

  

	 	15.2	 Termination by GSK. In addition to any other remedies
available at law or in equity, GSK may immediately terminate this Agreement in accordance with the following provisions of this Clause 15.2: 

  

	 	15.2.1	 Material Breach. Immutep commits a material breach of any of the terms of this
Agreement, including a breach of Immutep’s obligations pursuant to Clause 7, but excluding a breach of Immutep’s obligations pursuant to Clause 4 (which shall not be considered a material breach, except Clauses 4.12.4, a breach of which
shall constitute a material breach for the purposes of this Clause 15.2.1) and fails to cure such material breach within [***] of receipt of a written notice from GSK as to the material breach and requiring it to be remedied, or, with respect to any
breach other than a breach of a payment obligation, notwithstanding Immutep’s on-going obligation to perform the terms of this Agreement, if cure cannot be reasonably effected within such [***] period,
delivery by Immutep of a plan for curing such material breach that is sufficient to effect a cure within a reasonable timeframe, with assurances acceptable to GSK, and shall thereafter carry out the plan and cure the material breach within the
agreed timeframe. If Immutep has not cured the material breach accordingly, then GSK may terminate this Agreement immediately upon notice to Immutep. In the event of a good faith dispute with respect to the existence of a material breach, the effect
of the notice of termination shall be suspended until such time as the dispute is resolved pursuant to Clause 18. The failure to disclose information which is prohibited by Applicable Laws shall not constitute a material breach of this Agreement
pursuant to this Clause 15.2.1. 

  

	 	15.2.2	 Insolvency. Immutep is unable to pay its debts within the meaning of S. 123 of the Insolvency Act 1986
or any other equivalent law in any country (including for the avoidance of doubt, the law of France) or shall convene a meeting of its creditors or if a proposal shall be made for a voluntary arrangement within Part I of the Insolvency Act 1986 or
any other equivalent law in any country (including for the avoidance of doubt, the law of France) or a proposal for any other composition, scheme or arrangement with (or assignment for the benefit of) its creditors or a receiver,

  
 40 

					
	Confidential	  		  	Execution Copy

  

	 	 	 administrative receiver or similar officer is appointed over all or a substantial part of its undertaking or
assets or if a petition is presented or a meeting is convened for the purpose of considering a resolution or other steps are taken for its winding (other than for the purposes of reconstruction or amalgamation and whether by the presentation of a
winding up petition or otherwise) or for the making of an administration order. 

  

	 	15.2.3	 [***]. 

  

	 	15.3	 Termination by Immutep. 

 

	 	15.3.1	 In addition to any other remedies available at law or in equity, Immutep may immediately terminate this
Agreement in accordance with the following provisions of this Clause 15.3: 

  

	 	15.3.2	 Material Breach. GSK commits a material breach of any of the terms of this
Agreement and fails to cure such material breach within [***] of receipt of a written notice from Immutep as to the material breach and requiring it to be remedied, or, with respect to any breach other than a breach of a payment obligation,
notwithstanding GSK’s on-going obligation to perform the terms of this Agreement, if cure cannot be reasonably effected within such [***] period, delivery by GSK of a plan for curing such material breach
that is sufficient to effect a cure within a reasonable timeframe, with assurances acceptable to Immutep, and shall thereafter carry out the plan and cure the material breach within the agreed timeframe. If GSK has not cured the material breach
accordingly, then, Immutep may terminate this Agreement immediately upon notice to GSK. In the event of a good faith dispute with respect to the existence of a material breach other than with respect to GSK’s payment obligations pursuant to
Clause 8, the effect of the notice of termination shall be suspended until such time as the dispute is resolved pursuant to Clause 18, provided further that the resolution of such dispute is promptly commenced and diligently pursued by GSK. In the
event of a good faith dispute with respect to the existence of a breach of GSK’s payment obligations pursuant to Clause 8, the cure period shall be suspended upon initiation of a mediation and until such time as the dispute is resolved pursuant
to Section 18. 

  

	 	15.3.3	 Insolvency. GSK is unable to pay its debts within the meaning of S. 123 of the Insolvency Act
1986 or any other equivalent law in any country or shall convene a meeting of its creditors or if a proposal shall be made for a voluntary arrangement within Part I of the Insolvency Act 1986 or a proposal for any other composition, scheme or
arrangement with (or assignment for the benefit of) its creditors or a receiver, administrative receiver or similar officer is appointed over all or a substantial part of its undertaking or assets or if a petition is presented or a meeting is
convened for the purpose of considering a resolution or other steps are taken for its winding (other than for the purposes of reconstruction or amalgamation and whether by the presentation of a winding up petition or otherwise) or for the making of
an administration order. 

  

	 	15.3.4	 No Challenge. In the event that GSK or any of its Affiliates, anywhere in the world, institutes,
prosecutes or otherwise participates in (or in any way knowingly and intentionally aids any Third Party in instituting, prosecuting or participating in), at law or in equity or before any administrative or 

  
 41 

					
	Confidential	  		  	Execution Copy

  

	 	regulatory body, including the U.S. Patent and Trademark Office or its foreign counterparts, any claim, demand, action or cause of action for declaratory relief, damages or any other remedy, or for an enjoinment,
injunction or any other equitable remedy, including any interference, re- examination, opposition or any similar proceeding, alleging that any claim in a Monoclonal Antibody Patent is invalid, unenforceable or otherwise not patentable, Immutep shall
have the right to terminate the licence granted to GSK under such challenged Patent, on a patent-by-patent basis provided that: 

 

	 	(a)	 GSK receives written notice from Immutep as to the action Immutep requires to be resolved under this Clause
15.3.4; and 

  

	 	(b)	 GSK shall have a period no less than [***] to either: (i) resolve such action under this Clause 15.3.4 or
(ii) deliver a plan reasonably necessary for resolving such action under this Clause 15.3.4. In the event that GSK delivers a plan for resolving the aforementioned action, Immutep shall not be entitled to terminate the licence granted to GSK
under such challenged Patent until such plan has been implemented by GSK in its entirety. 

  

	 	(c)	 following the receipt of a written notice from Immutep as to the action Immutep requires to be rectified under
this Clause 15.3.4, and GSK fails to rectify or cure such action pursuant to this Clause 15.3.4 within [***] and the delivery by GSK of a plan for curing such material breach that is sufficient to effect a cure within a reasonable timeframe, with
assurances acceptable to GSK, and shall thereafter carry out the plan and cure the material breach within the agreed timeframe. If GSK has not cured the material breach accordingly, then, Immutep may terminate the licence granted to GSK under such
challenged Patent immediately upon notice to GSK. In the event of a good faith dispute with respect to the existence of a material breach, the effect of the notice of termination shall be suspended until such time as the dispute is resolved pursuant
to Clause 18, provided further that the resolution of such dispute is promptly commenced and diligently pursued by GSK. 

 16
CONSEQUENCES OF TERMINATION 
  

	 	16.1	 Upon any termination or expiration of this Agreement: 

 

	 	16.1.1	 General. Such termination or expiration of this Agreement shall: (i) be without prejudice to any
other damage or legal redress that a Party may be entitled to, and (ii) shall not release a Party from any indebtedness, liability or other obligation incurred under this Agreement by such Party prior to the date of termination or expiration of
this Agreement. 

  

	 	16.1.2	 Expiration of Financial Obligations. On the expiration
of all royalty obligations with respect to the Licensed Product that is being commercialised by GSK in a particular country, if any, subject to the terms and conditions of this Agreement, GSK shall have a perpetual, non- exclusive, fully-paid and
royalty-free right and licence, with the right to grant sublicenses, under all of Immutep’s rights in and to the Immutep Background IP, Collaboration IP and/or Managed Patents assumed by Immutep under Clause 10.1 to continue to make, have made,
use, sell, offer to sell and import the Monoclonal Antibody and the Licensed Product in the Field in such country. 

  
 42 

					
	Confidential	  		  	Execution Copy

  

	 	16.1.3	 Termination. All licenses granted to GSK and Immutep, as applicable, under this Agreement shall, save as
provided in Clause 16.1.4 and subject to Clause 16.1.4, terminate on a country-by-country basis to the extent that they relate to a country GSK has selected for the
termination of its rights under this Agreement. 

  

	 	16.1.4	 GSK Continuing Rights. Upon the termination of this Agreement by GSK
pursuant to Clause 15.2.1 or Clause 15.2.2, GSK shall continue to have the exclusive right to research, develop and commercialise the Monoclonal Antibody and/or the Licensed Product and the covenant of Immutep in Clause 7, together with the licence
granted in Clause 2.1 shall continue in full force and effect subject only to the payment by GSK of the applicable amounts set out in Clause 8. If GSK terminates this Agreement pursuant to Clause 15.2.1 and/or Clause 15.2.2, GSK shall then decrease
any milestone and royalty payment payable to Immutep in respect of the Licensed Product by fifty percent (50%), for so long as GSK has the right to commercialise such Licensed Product on the terms set out under this Agreement and Immutep shall:

  

	 	(a)	 immediately upon termination of this Agreement, assign to GSK all of the Immutep Licensed Arising IP, Immutep Non-Licensed Arising IP, the Immutep interest in the Joint Licensed Arising IP and the Immutep interest in the Joint Non-Licensed Arising IP, and the Immutep Know-How; and 

  

	 	(b)	 use all reasonable endeavours to procure as soon as reasonably practicable that GSK becomes a direct licensee
pursuant to the INSERM Agreement and the Merck-Serono Agreement with such rights as to enable GSK to fulfil its rights and obligations under this Agreement as it exists prior to its termination in accordance with this Clause 16.1.4.

  

	 	16.1.5	 Return of Information. Subject to Clause 16.1.3, with respect to surviving licenses and all related Know-How, regulatory documentation and clinical data, each Party shall, at the request of the other Party, return, or destroy (upon the requesting Party’s request) all Confidential Information of the other
Party in its possession, save for one copy of each document containing Confidential Information which may be retained for purposes of assessing on-going compliance with the provisions of Clause 12.

  

	 	16.1.6	 Survival. The following rights and obligations shall survive such termination or expiration:
(i) the confidentiality obligations set forth in Clause 12; (ii) all then-existing payment obligations owed by GSK to Immutep pursuant to Clause 8 and all obligations for record-keeping and accounting records in accordance with the terms of
this Agreement; (iii) the Parties’ rights with respect to the ownership of intellectual property as set forth in Clauses 9 and 10; (iv) the obligations on indemnity pursuant to Clause 14.2; and (v) the Parties’ rights and
immunities pursuant to the disclaimers set forth in Clauses 14.7 and 14.8. 

  

	 	16.1.7	 Immutep Rights Upon Termination. If GSK terminates this
Agreement without cause pursuant to Clause 15.2.3 or if Immutep terminates this Agreement pursuant to Clause 15.3.2 and Clause 15.3.3, at Immutep’s request, all rights and licenses granted to GSK relating to the Monoclonal Antibody, the Immutep
Intellectual Property, or the Merck-Serono IP, shall terminate and revert back to Immutep and all respective obligations of GSK shall terminate accordingly upon such termination. 

 

	 	16.1.8	 Further Immutep Rights Upon Termination.
Immutep shall not have any further rights in respect of the development or commercialisation of the Monoclonal Antibody and/or Licensed Product if a Safety Concern exists on the date of termination of this Agreement. In the event that a Safety
Concern does not exist: 

  
 43 

					
	Confidential	  		  	Execution Copy

  

	 	(a)	 the Parties shall negotiate in good faith, for a period of up to [***] from the date of termination, a royalty
that Immutep, its Affiliates or Sub-licensees would pay to GSK on Net Sales (the definition of which shall apply to this Clause 16.1.8 (a) mutatis mutandis) of the Licensed Product, for
the right to use or have used, develop, manufacture, import, sell and offer to sell Licensed Product in the Field, in the Territory, the level of such royalty to reflect each of: (i) the investment by GSK in the development of such Monoclonal
Antibody and/or Licensed Product, (ii) the extent of the clinical studies performed by GSK with such Monoclonal Antibody and/or Licensed Product, and (iii) the stage of development of such Monoclonal Antibody and/or Licensed Product.

  

	 	(b)	 GSK shall grant to Immutep a non-exclusive licence under the GSK
Background IP, the GSK Non-Licensed Arising IP, the GSK Licensed Arising IP, GSK Programme IP, and GSK Licensed Arising IP and Immutep’s interest in the Joint Licensed Arising IP assigned to GSK purusant
to Clause 9.4.1 solely for the purpose to use or have used, develop, manufacture, import, sell and offer to sell the Licensed Product (with the right to grant sublicenses solely for the purpose to use or have used, develop, manufacture, import, sell
and offer to sell the Licensed Product). 

  

	 	(c)	 GSK shall transfer to Immutep ownership at Immutep’s sole cost, of all Regulatory Approvals and
applications for such Regulatory Approvals reasonably required by Immutep to use or have used, develop, manufacture, import, sell and offer to sell the Licensed Product. 

 

	 	(d)	 GSK shall provide Immutep with copies of GSK clinical data and GSK technology reasonably required by Immutep to
use or have used, develop, manufacture, import, sell and offer to sell the Licensed Product as manufactured, formulated and, if applicable, approved at the date of termination. 

 

	 	16.1.9	 Continuation of Clinical Studies. In the event that the Agreement terminates during any clinical trial
sponsored by GSK pertaining to the Monoclonal Antibody and/or the Licensed Product, GSK shall at its own expense continue such clinical trials as required by Applicable Laws and ethical standards. 

 

	 	16.2	 Supplies of Licensed Products After Termination. In the event that this Agreement is terminated after
First Commercial Sale of the Licensed Product, GSK and its Affiliates and permitted Sub-licensees shall have the right, for a period of [***] following such termination, to sell in the Field in the Territory
stocks of Licensed Products existing at the time of such termination for which Marketing Authorisation in the Territory has been granted, subject to all applicable payment and other related obligations in this Agreement, until such stock is
exhausted. Upon expiration of such [***] period (or such other period as the Parties shall agree) the Parties shall agree how to deal with any and all quantities of any Licensed Products in GSK’s possession or control. 

 

	 	16.3	 Accrued Rights; Surviving Provisions of the Agreement. 

 

	 	16.3.1	 Except as provided in Clauses 16.1.7 through Clause 16.3 or as otherwise expressly stated under this Agreement,
expiration or termination of this Agreement (in its entirety or with respect to any particular Research Program) shall be without prejudice to any rights or remedies provided at law or equity that either Party may otherwise have. Such expiration or
termination shall not relieve either Party from obligations that are expressly indicated under Clause 16.3.2 to survive expiration or termination of this Agreement. 

  
 44 

					
	Confidential	  		  	Execution Copy

  

	 	16.3.2	 In addition to the provisions of this Agreement that survive termination of this Agreement by operation of the
provisions of Clause 16, Clause 1, Clause 8.14, Clause 8.15, the remainder of Clause 8 to the extent that payments are outstanding, Clauses 9, 12, 18 and 19 (except 19.1) shall survive any termination or expiration of this Agreement in its entirety
for any reason, in accordance with the respective terms stated therein and for the duration stated therein, and where no duration is stated, shall survive indefinitely. 

17 NOTICES 
  

	 	17.1	 Any notice to be given pursuant to this Agreement shall be in writing in the English language and shall
be delivered by overnight courier, by registered, recorded delivery or certified mail (postage prepaid) or by facsimile confirmed by registered, recorded delivery or certified mail (postage prepaid) to the address or facsimile number of the
recipient Party set out below or such other address or facsimile number as a Party may from time to time designate by written notice to the other Party. 

Address of Immutep 

Immutep S.A. 
 Parc Club Orsay

 2 rue Jean Rostand 
 91893
Orsay cedex 
 France 
 Fax:
+33 1 69078221 
 For the attention of the Président Directeur Général 

Address of GSK  

GlaxoSmithKline 
 980 Great West
Road 
 Brentford, Middlesex TW8 9GS 

United Kingdom 
 Fax: +44 20
8047 6897 
 For the attention of Legal Operations, Business Development Transactions 

and to: 
 GlaxoSmithKline 

709 Swedeland Road 
 UW2318 

King of Prussia, PA 19406 
 USA

 Fax No: +1 610 270 6299 

For the attention of the Senior Vice President, Worldwide Business Development and R&D Finance 

 

	 	17.2	 Any notice given pursuant to this Clause 17 shall be deemed to have been received:

  

	 	17.2.1	 in the case of delivery by courier or sending by mail on the day of receipt provided receipt occurs on a
Business Day of the recipient Party or otherwise on the next following Business Day of the recipient; or 

  
 45 

					
	Confidential	  		  	Execution Copy

  

	 	17.2.2	 in the case of facsimile, on acknowledgement by the recipient facsimile receiving equipment on a Business Day
if the acknowledgement occurs before 5.00 pm local time of the recipient and in any other case on the next following Business Day. 

  

	 	17.3	 Any notice that is required in this Agreement to be given in writing shall include notices by fax or
post but shall not include any notice by e-mail. 

 18 DISPUTE RESOLUTION 

 

	 	18.1	 Dispute Resolution. Prior to the commencement of any litigation with respect
to this Agreement, the Executive Officer or designates of the Party considering commencement of such litigation shall notify the Executive Officer or designate of the other Party that such litigation is being contemplated. The Parties’
Executive Officers shall make themselves available to discuss the dispute, difference or question, as the case may be (the “Unresolved Matter”), and use good faith efforts to resolve such Unresolved Matter within the
[***] following the delivery of such notice. Notwithstanding the provisions of this Clause 18.1 or of Clause 18.2, each Party shall be free to seek temporary injunctive relief in court as the situation may necessitate based upon any irreparable harm
which may ensue while awaiting the resolution of any proceeding authorized under this Clause 18. 

  

	 	18.2	 If the Unresolved Matter is not resolved within such [***] period, the Parties agree to submit it for non-binding mediation (with the understanding that the role of the mediator shall not be to render a decision but to assist the Parties in reaching a mutually acceptable resolution) in London UK (or such other
location as may be mutually agreed upon by the Parties. If the Unresolved Matter is not resolved within such [***] of the delivery of such notice either Party may, subject to Clause 18.3, make such applications to court as it sees fit. For clarity,
the Parties understand and agree that no matter which is subject to the final decision-making authority of a Party as expressly set forth in Clause 6.2 or Clause 10.3 shall be subject to any review under this Clause 18.2 or otherwise under this
Agreement or in court or by any other legal tribunal or proceeding at law or in equity. The mediation is non-binding and Parties shall not be obliged to accept or follow any recommendation of the mediator.

  

	 	18.3	 Governing Law. This Agreement and any dispute arising from the performance
or breach hereof shall be governed by and construed and enforced in accordance with the laws of England and the Parties, hereby irrevocably submit to the exclusive jurisdiction of the English Courts. 

19 MISCELLANEOUS 
  

	 	19.1	 Assignment. Neither this Agreement nor any right or obligation hereunder shall be
assignable by either Party to any third party without the prior written consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, either Party may assign this Agreement and the
rights, affirmative obligations and interests of such Party, in whole or in part, without any consent of the other Party, to an Affiliate, or to a Third Party that acquires all or substantially all of the business or assets of such Party to which
this Agreement pertains (whether by merger, reorganization, acquisition, sale or otherwise) and agrees in writing to be bound by the terms and conditions of this Agreement. No assignment shall be valid or effective unless and until the assignee or
transfer shall agree in writing to be bound by the provisions of this Agreement. 

  

	 	19.2	 Force Majeure. No Party shall be held liable or responsible to the other Party nor be deemed to be in
default under, or in breach of any provision of, this Agreement for failure or delay in fulfilling or performing any obligation of this Agreement when 

  
 46 

					
	Confidential	  		  	Execution Copy

  

	 	such failure or delay is due to force majeure, and without the fault or negligence of the Party so failing or delaying. For purposes of this Agreement, force majeure is defined as causes beyond the
reasonable control of the Party, including: acts of God; acts, regulations, or laws of any government; war; civil commotion; destruction of production facilities or materials by fire, flood, earthquake, explosion or storm; labour disturbances; and
failure of public utilities or common carriers. In such event Immutep or GSK, as the case may be, shall promptly notify the other Party of such inability and of the period for which such inability is expected to continue. The Party giving such
notice shall thereupon be excused from such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled for up to a maximum of [***], after which time Immutep and GSK, will meet to agree a
mutually-acceptable way forward. To the extent possible, each Party shall use reasonable endeavours to minimize the duration of any force majeure. 

  

	 	19.3	 Waiver. Neither Party may waive or release any of its rights or interests in this Agreement except in
writing. The failure of either Party to assert a right under this Agreement or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any
such term or condition. No waiver by either Party of any condition or term in any one or more instances shall be construed as a continuing waiver of such condition or term or of another condition or term. 

 

	 	19.4	 Severability. If any provision of this Agreement is held invalid, illegal or unenforceable in any
jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties. All other provisions of this Agreement shall remain in full force and effect in
such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such
provision in any other jurisdiction. 

  

	 	19.5	 Entire Agreement; Amendment. This Agreement, together with its Schedules, set out all the covenants,
promises, agreements, warranties, representations, conditions and understandings between the Parties with respect to the subject matter hereof and supersedes and terminates all prior agreements and understandings, written or oral, between the
Parties with respect to such subject matter. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized representative of each Party.

  

	 	19.6	 Independent Contractors. Nothing in this Agreement shall be construed to create any relationship of
employer and employee, agent and principal, partnership or joint venture between the Parties. Each Party is an independent contractor. Neither Party shall assume, either directly or indirectly, any liability of or for the other Party. Neither Party
shall have the authority to bind or obligate the other Party, and neither Party shall represent that it has such authority. 

  

	 	19.7	 Further Actions. Each Party shall execute, acknowledge and deliver such further instruments, and do all
such other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. 

  

	 	19.8	 Parties in Interest. All of the terms and provisions of this Agreement shall be binding upon, and shall
inure to the benefit of and be enforceable by the Parties and their respective successors and their respective permitted assigns. 

  

	 	19.9	 Construction of Agreement. The terms and provisions of this Agreement represent the results of
negotiations between the Parties and their representatives, each of which has been represented by counsel of its own choosing and neither of which has acted under duress or compulsion, whether legal, economic or otherwise. Accordingly, each of the
Parties hereby waives the application in connection with the 

  
 47 

					
	Confidential	  		  	Execution Copy

  

	 	interpretation and construction of this Agreement of any rule of law to the effect that ambiguous or conflicting terms or provisions contained in this Agreement shall be interpreted or construed against the Party whose
attorney prepared the Agreement as executed or any earlier draft of this Agreement. 

  

	 	19.10	 Third Parties. Except where expressly stated in this Agreement to the contrary no person who is not a
Party to this Agreement (or his successors or permitted assignees under this Agreement) has any rights under the Contracts (Rights of Third Parties) Act 1999 or otherwise to enforce or enjoy the benefit of any term of this Agreement.

  

	 	19.11	 Fees and Expenses. Each Party shall pay its respective legal and other fees and expenses associated with
the preparation and negotiation of this Agreement. 

  

	 	19.12	 Supremacy. In the event of any conflict or uncertainty between the terms of this Agreement and any
Schedules hereto, the terms of the main body of this Agreement, that is Clauses 1 to 19 inclusive, shall supersede and control. 

  

	 	19.13	 Counterparts. This Agreement may be signed in counterparts, each and every one of which shall be deemed
an original, notwithstanding variations in format or file designation which may result from the electronic transmission, storage and printing of copies of this Agreement from separate computers or printers. Facsimile signatures and signatures
transmitted via pdf shall be treated as original signatures. 

  

	 	19.14	 Binding Effect. This Agreement will be binding upon and inure to the benefit of the Parties hereto and
their respective successors and permitted assigns. 

 [THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 48 

					
	Confidential	  		  	Execution Copy

  

 IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties, have executed, or caused
this Agreement to be executed by their duly authorized representatives, as of the Effective Date. 
  

			
	IMMUTEP S.A.
		
	By:	 	      

	
	Name:
	
	Title:
	
	GLAXO GROUP LIMITED
		
	By:	 	
                     
                                        

	
	Name:
	
	Title:

  
 49 

					
	Confidential	  		  	Execution Copy

  

 SCHEDULES 1- 10 

[***] 

  
 50EX-10.1

 Exhibit 10.1 

Execution Version 
  

 
  

NINTH AMENDMENT 
 TO

 FOURTH AMENDED AND RESTATED CREDIT AGREEMENT 

AND 
 THIRD AMENDMENT

 TO 
 FOURTH
AMENDED AND RESTATED GUARANTEE AND COLLATERAL 
 AGREEMENT 

dated as of 
 September 23,
2019 
 among 
 GENESIS
ENERGY, L.P., 
 as the Borrower, 

WELLS FARGO BANK, NATIONAL ASSOCIATION, 

as Administrative Agent and Issuing Bank, 

BANK OF AMERICA, N.A. AND BANK OF MONTREAL, 

as Co-Syndication Agents, 

U.S. BANK NATIONAL ASSOCIATION, 

as Documentation Agent, 
 and 

The Lenders Party Hereto 
  

 
  

 NINTH AMENDMENT TO FOURTH AMENDED AND RESTATED CREDIT 

AGREEMENT AND THIRD AMENDMENT TO FOURTH AMENDED AND RESTATED 

GUARANTEE AND COLLATERAL AGREEMENT 

This NINTH AMENDMENT TO FOURTH AMENDED AND RESTATED CREDIT AGREEMENT AND THIRD AMENDMENT TO FOURTH AMENDED AND RESTATED GUARANTEE AND
COLLATERAL AGREEMENT, dated as of September 23, 2019 (collectively, this “Ninth Amendment”), is by and among GENESIS ENERGY, L.P., a Delaware limited partnership (the “Borrower”), the other Grantors
(as defined in the Guarantee and Collateral Agreement referred to below) party hereto, WELLS FARGO BANK, NATIONAL ASSOCIATION, as administrative agent (in such capacity, together with its successors in such capacity, the
“Administrative Agent”) for the lenders party to the Credit Agreement referred to below (the “Lenders”), and the Lenders party hereto. 

RECITALS 

A.    The Borrower, the Lenders party thereto, the Administrative Agent and the other agents and Issuing Banks referred to
therein are parties to that certain Fourth Amended and Restated Credit Agreement, dated as of June 30, 2014, as amended by that certain First Amendment to Fourth Amended and Restated Credit Agreement, dated as of August 25, 2014, that
certain Second Amendment to Fourth Amended and Restated Credit Agreement and Joinder Agreement, dated as of July 17, 2015, that certain Third Amendment to Fourth Amended and Restated Credit Agreement, dated as of September 17, 2015, that
certain Fourth Amendment to Fourth Amended and Restated Credit Agreement and Joinder Agreement, dated as of April 27, 2016, that certain Fifth Amendment to Fourth Amended and Restated Credit Agreement and Second Amendment to Fourth Amended and
Restated Guarantee and Collateral Agreement, dated as of May 9, 2017, that certain Sixth Amendment to Fourth Amended and Restated Credit Agreement, dated as of July 28, 2017, that certain Seventh Amendment to Fourth Amended and Restated
Credit Agreement, dated as of August 28, 2018, and that certain Eighth Amendment to Fourth Amended and Restated Credit Agreement, dated as of October 11, 2018 (as so amended, the “Credit Agreement”), pursuant to which the
Lenders have made certain Loans and provided certain Committed Amounts (subject to the terms and conditions thereof) to the Borrower; 
 B.
    The Borrower, the Administrative Agent and the other parties thereto are parties to that certain Fourth Amended and Restated Guarantee and Collateral Agreement, dated as of June 30, 2014, as amended by that certain First
Amendment to Fourth Amended and Restated Guarantee and Collateral Agreement, dated as of September 17, 2015, and that certain Fifth Amendment to Fourth Amended and Restated Credit Agreement and Second Amendment to Fourth Amended and Restated
Guarantee and Collateral Agreement, dated as of May 9, 2017 (as so amended, the “Guarantee and Collateral Agreement”); and 

C.     The Borrower wishes, and the Lenders signatory hereto and the Administrative Agent are willing, to amend the Credit
Agreement and the Guarantee and Collateral Agreement as more fully described herein. 

  
 1 

 NOW, THEREFORE, in consideration of the premises and the mutual covenants herein
contained, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

SECTION 1.     Defined Terms. Each capitalized term used herein but not otherwise defined herein has the meaning
given such term in the Credit Agreement. Unless otherwise indicated, all article, schedule, exhibit and section references in this Ninth Amendment refer to articles, schedules, exhibits and sections of the Ninth Amendment. 

SECTION 2.    Amendments to Credit Agreement. As of the Ninth Amendment Effective Date (as defined below), the
Credit Agreement is amended as follows: 
  

	 	(a)	 Section 1.01 of the Credit Agreement is hereby amended by adding the following new definitions in their proper
alphabetical order: 

 “Alkali Group” means, collectively, Genesis Alkali Holdings Company, LLC, Genesis
Alkali Holdings, LLC, Genesis Alkali, LLC, Genesis Alkali Wyoming, LP, Genesis Specialty Alkali, LLC and their respective subsidiaries. 

“Alkali Group Distribution Policy” means the distribution policy of Genesis Alkali Holdings Company, LLC as in effect on the
Ninth Amendment Effective Date and set forth on Exhibit J hereto. 
 “Alkali Group Distribution Policy Trigger” means
the first to occur of (a) the Alkali Group Distribution Policy ceasing to be in effect, (b) the Alkali Group Distribution Policy being amended or modified in such way as to further limit in any material way the cash distributions from
Genesis Alkali Holdings Company, LLC to its common equityholders, and (c) Genesis Alkali Holdings Company, LLC failing to comply with the Alkali Group Distribution Policy in any material respect. 

“Alkali Preferred Units” means (a) the redeemable preferred units issued by Genesis Alkali Holdings Company, LLC to GSO
Capital Partners LP, a Delaware limited partnership, for up to $350,000,000 of proceeds pursuant to the unit purchase agreement dated as of and as in effect on the Ninth Amendment Effective Date or (b) other redeemable preferred units issued by
Genesis Alkali Holdings, LLC on terms no less favorable to it than the terms of the preferred units described in clause (a) to the extent that the net proceeds thereof (i) do not exceed the amount necessary to fully redeem the preferred
units described in clause (a) (plus all accrued and unpaid distributions on such preferred units and the amount of all premiums, fees and expenses incurred in connection therewith) and (ii) are used to fully redeem the preferred units described
in clause (a). 
 “Beneficial Ownership Certification” means a certification regarding beneficial ownership as required by
the Beneficial Ownership Regulation. 
 “Beneficial Ownership Regulation” means 31 C.F.R. § 1010.230. 

  
 2 

 “Ninth Amendment Effective Date” means the “Ninth Amendment Effective
Date” as defined in that certain Ninth Amendment to Fourth Amended and Restated Credit Agreement and Third Amendment to Fourth Amended and Restated Guarantee and Collateral Agreement, dated as of September 23, 2019, among the Borrower, the
Administrative Agent and the Lenders party thereto. 
  

	 	(b)	 Section 1.01 of the Credit Agreement is hereby amended by amending and restating the second paragraph of
the definition of “Applicable Margin” as follows: 

 “For purposes of the Leverage-Based Pricing
Grid, the Applicable Margin for any date shall be determined by reference to the Consolidated Leverage Ratio (provided that, as of the last day of any fiscal quarter ending prior to July 1, 2016, if the Consolidated Leverage Ratio is greater
than 5.00 to 1.00, Level V shall apply) as of the last day of the fiscal quarter most recently ended and any change shall (a) become effective upon the delivery to the Administrative Agent of financial statements pursuant to
Section 5.01(a) or (b) for such quarter and (b) apply to Loans outstanding on such delivery date or made on and after such delivery date but prior to the effective date of the next such change. Notwithstanding the foregoing, at any
time during which the applicable Borrower Party has failed to deliver such financial statements to the Administrative Agent when due, the Consolidated Leverage Ratio shall be deemed, solely for the purpose of this definition, to be (x) prior to
July 1, 2016, Level V and (y) on or after July 1, 2016, Level VII, until such time as the applicable Borrower Party shall deliver such financial statements.” 

 

	 	(c)	 Section 1.01 of the Credit Agreement is hereby amended by adding the following new clause (c)(iii) to the
definition of “Consolidated EBITDA”: 

 “with respect to the Alkali Group, minus the amount of cash
distributions paid to the holders of Alkali Preferred Units.” 
  

	 	(d)	 Section 1.01 of the Credit Agreement is hereby amended by amending and restating clause (d)(ii) of the
definition of “Consolidated EBITDA” as follows: 

 “cash dividends or distributions (or with respect
to NEJD SPE 1, loan payments under the NEJD Intercompany Note) received (if any) by the Borrower or any Restricted Subsidiary from Unrestricted Subsidiaries (other than the Alkali Group prior to the occurrence of the Alkali Group Distribution Policy
Trigger), Joint Ventures, equity investees and any other Person accounted for by the Borrower by the equity method of accounting, or any other Person that is not a Subsidiary (plus, with respect to the Alkali Group after the occurrence of the Alkali
Group Distribution Policy Trigger, reserves for maintenance capital) in substitution of any GAAP items reflected in such period attributable to income/loss of such Persons; provided, that all such dividends or distributions with respect to a
relevant accounting period that the Borrower or any Restricted Subsidiary receives within 15 days after such accounting period shall be included as if such amounts had been received during such accounting period.” 

  
 3 

	 	(e)	 Section 1.01 of the Credit Agreement is hereby amended by amending and restating clause (c)(iii) of the
definition of “Pro Forma Basis” as follows: 

 “with respect to such Substantial Transaction, in
making any determination of Adjusted Consolidated EBITDA, pro forma effect shall be given to any such Substantial Transaction if effected during the respective Calculation Period or Test Period as if same had occurred on the first day
of the respective Calculation Period or Test Period, as the case may be, and, at the Borrower’s election by written notice to the Administrative Agent as contemplated by clause (iv)(a)(x) below, but only to the extent approved by the
Administrative Agent and a majority of the Arrangers pursuant to such clause (and with respect to any redemption of the Alkali Preferred Units constituting a Substantial Transaction, only if concurrently with such redemption, each member of the
Alkali Group is designated as a Restricted Subsidiary), with respect to adjustments beyond the mere combination of the relevant historical financial information, including for factually supportable and identifiable cost savings and reduction of
expenses which would otherwise be accounted for as an adjustment pursuant to Article 11 of Regulation S-X under the Securities Act, (collectively such adjustments,
“Non-Historical Pro Forma Adjustments”), as if such cost savings or reduction of expenses or other adjustments were realized commencing on the first day of the respective period; and”

  

	 	(f)	 Section 1.01 of the Credit Agreement is hereby amended by replacing “each Arranger” in each
place it appears in clause (c)(iv) of the definition of “Pro Forma Basis” with “the Administrative Agent and a majority of the Arrangers”. 

 

	 	(g)	 Section 1.01 of the Credit Agreement is hereby amended by amending and restating the definition of
“Substantial Transaction” as follows: 

 ““Substantial Transaction” means
(a) any Permitted Acquisition, any acquisition that results in a Joint Venture, any acquisition that is consummated through an Unrestricted Subsidiary or a Joint Venture, or any Divestiture in respect of which the aggregate Acquisition
Consideration (or, in the case of a Divestiture, the consideration paid by the purchaser if calculated in the same manner as the definition of Acquisition Consideration) is in excess of $25,000,000 or (b) any redesignation of an Unrestricted
Subsidiary as a Restricted Subsidiary in accordance with the definition of “Restricted Subsidiary”; provided, that the Borrower’s Divestiture from time to time in one or more transactions of all or any portion of the VKGC Business
and/or the Wink Business shall not be considered for purposes of (i) determining if any Divestiture constitutes a Substantial Transaction or (ii) performing calculations on a Pro Forma Basis pursuant to this Agreement.” 

 

	 	(h)	 Section 1.01 of the Credit Agreement is hereby amended by amending and restating the definition of
“Unrestricted Subsidiary” as follows: 

 ““Unrestricted Subsidiary” means
(1) any Subsidiary (a) that is listed as an Unrestricted Subsidiary on Schedule 3.18(a) (until such time as such Subsidiary 

  
 4 

 
may be redesignated as a Restricted Subsidiary in accordance with the definition of “Restricted Subsidiary”) or that becomes a Subsidiary after the date hereof and, at the time it
becomes a Subsidiary, is designated as an Unrestricted Subsidiary pursuant to a written notice from the Borrower to the Administrative Agent, (b) which has not acquired any assets (other than as not prohibited by this Agreement) from the
Borrower or any Restricted Subsidiary, and (c) that has no Indebtedness, Guarantee obligations or other obligations other than Non-Recourse Obligations, except as expressly permitted pursuant to Sections
5.13(c) and 6.04(g) and, in the case of NEJD SPE 2, except for recourse pursuant to the NEJD SRCA, the NEJD Intercompany Financing Agreements and the NEJD Consent (subject to limitations on amendment of such documents set forth in the Loan
Documents, the NEJD Intercompany Financing Agreements and the NEJD Consent) and (2) each member of the Alkali Group (until such time as such member of the Alkali Group may be redesignated as a Restricted Subsidiary in accordance with the
definition of “Restricted Subsidiary”). Any Restricted Subsidiary (other than the General Partner) may be redesignated as an Unrestricted Subsidiary pursuant to a written notice from the Borrower to the Administrative Agent;
provided that, after giving effect to such redesignation, (i) no Default or Event of Default shall have occurred and be continuing and (ii) the Borrower shall be in compliance on a Pro Forma Basis with Section 6.14;
provided further that, an Unrestricted Subsidiary that has previously been redesignated as a Restricted Subsidiary may not be subsequently redesignated as an Unrestricted Subsidiary.” 

 

	 	(i)	 Section 3.18(a) of the Credit Agreement is hereby amended by replacing “Effective Date” in each
place it appears therein with “Ninth Amendment Effective Date”. 

  

	 	(j)	 Section 5.02 of the Credit Agreement is hereby amended by (i) deleting the “and” from the
end of Section 5.02(c), (ii) replacing the “.” at the end of Section 5.02(d) with “; and” and (iii) adding the following new Section 5.02(e): 

“to the best of the Borrower’s knowledge, any change in the information provided in the Beneficial Ownership Certification that would
result in a change to the list of beneficial owners identified in parts (c) or (d) of such certification.” 
  

	 	(k)	 Section 5.13(c) of the Credit Agreement is hereby amended and restated in its entirety as follows:

 “Notwithstanding any provision of the Loan Documents to the contrary, the Borrower and the other Borrower Parties
may incur Guarantee obligations in the ordinary course of business consisting of Guarantees of performance obligations of Unrestricted Subsidiaries as long as such Guarantees do not constitute Guarantees of payment or Guarantees of performance of
obligations that would result in the payment of any Indebtedness; provided, that, (i) in the case of Guarantees of performance obligations of any Person in the Alkali Group, the aggregate amount that has been or could reasonably be
expected to be incurred pursuant to all such performance Guarantees is not greater than $145,000,000 outstanding at any one time, and (ii) the amount that has been or could reasonably be expected to be incurred pursuant to all other such
performance Guarantees is not greater than $1,000,000 in the aggregate.” 

  
 5 

	 	(l)	 Section 6.04(b) of the Credit Agreement is hereby amended and restated in its entirety as follows:

 “(i) Investments by it existing on the date hereof and set forth on Schedule 6.04, (ii) additional
Investments in the Equity Interests of any Restricted Subsidiaries, and (iii) any Investments in any of the Alkali Group, if as a result of, and simultaneously with, such Investment, each member of the Alkali Group becomes a Restricted
Subsidiary;” 
  

	 	(m)	 Section 6.04(g) of the Credit Agreement is hereby amended and restated in its entirety as follows:

 “Investments in Unrestricted Subsidiaries (other than Investments in the Alkali Group); provided, that all
such Investments in Unrestricted Subsidiaries in the aggregate outstanding at any one time shall not exceed an amount equal to 2.5% of Consolidated Net Tangible Assets as of the most recent delivery of financial statements pursuant to
Section 5.01(a) or Section 5.01(b);” 
  

	 	(n)	 Section 6.04(h) of the Credit Agreement is hereby amended and restated in its entirety as follows:

 “Investments in any Person in the Alkali Group on the Ninth Amendment Effective Date and for so long thereafter as
such Person is not a Restricted Subsidiary; provided, that the aggregate outstanding amount of all Investments (valued at the time of the making thereof and without giving effect to any write-downs or write-offs thereof) permitted by this
Section 6.04(h) shall not, at any one time and without duplication, exceed the sum of (x) $1,350,000,000 plus (y) the lesser of (1) the amount of any cash distributions made following the Ninth Amendment Effective Date to the Borrower
and the Restricted Subsidiaries by the Alkali Group and (2) $350,000,000;” 
  

	 	(o)	 Section 6.04(n) of the Credit Agreement is hereby amended and restated in its entirety as follows:

 “such other Investments (other than Investments in any Joint Venture or Unrestricted Subsidiary) not otherwise
permitted by the foregoing clauses in this Section 6.04; provided, that all such Investments in the aggregate outstanding at any one time shall not exceed an amount equal to 7.5% of Consolidated Net Tangible Assets as of the most recent
delivery of financial statements pursuant to Section 5.01(a) or Section 5.01(b).” 

  
 6 

	 	(p)	 Section 6.06(f) of the Credit Agreement is hereby amended and restated in its entirety as follows:

 “the issuance, sale or other disposition of Equity Interests in or of any Unrestricted Subsidiary or any Joint
Venture;” 
  

	 	(q)	 The Credit Agreement is hereby amended by adding the following new Section 6.21: 

“Alkali Group. It will not permit any member of the Alkali Group to (a) create, incur, assume or permit to exist any
Indebtedness for borrowed money or Disqualified Equity (other than the Alkali Preferred Units) prior to such date that all members of the Alkali Group constitute Restricted Subsidiaries or (b) remain an Unrestricted Subsidiary after the
redemption of all Alkali Preferred Units.” 
  

	 	(r)	 The Credit Agreement is hereby amended by adding the following new Section 9.21: 

“Acknowledgement Regarding Any Supported QFCs. To the extent that the Loan Documents provide support, through a guarantee or
otherwise, for Hedging Agreements or any other agreement or instrument that is a QFC (such support, “QFC Credit Support” and each such QFC a “Supported QFC”), the parties acknowledge and agree as follows with
respect to the resolution power of the Federal Deposit Insurance Corporation under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act (together with the regulations promulgated thereunder,
the “U.S. Special Resolution Regimes”) in respect of such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the Loan Documents and any Supported QFC may in fact be stated to be governed
by the laws of the State of New York and/or of the United States or any other state of the United States): 
 (a) In the event a Covered
Entity that is party to a Supported QFC (each, a “Covered Party”) becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any
interest and obligation in or under such Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC or such QFC Credit Support) from such Covered Party will be effective to the same extent as the transfer would
be effective under the U.S. Special Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States. In the
event a Covered Party or a BHC Act Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Loan Documents that might otherwise apply to such Supported QFC or any QFC Credit
Support that may be exercised against such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the Supported QFC and the Loan Documents were
governed by the laws of the United States or a state of the United States. Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the
rights of any Covered Party with respect to a Supported QFC or any QFC Credit Support. 

  
 7 

 (b) As used in this Section 9.21, the following terms have the following meanings: 

“BHC Act Affiliate” of a party means an “affiliate” (as such term is defined under, and interpreted in accordance
with, 12 U.S.C. 1841(k)) of such party. 
 “Covered Entity” means any of the following: 

 

	 	i.	 a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. §
252.82(b); 

  

	 	ii.	 a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. §
47.3(b); or 

  

	 	iii.	 a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. §
382.2(b). 

 “Default Right” has the meaning assigned to that term in, and shall be interpreted in
accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable. 
 “QFC” has the meaning assigned to the term
“qualified financial contract” in, and shall be interpreted in accordance with, 12 U.S.C. 5390(c)(8)(D).” 
  

	 	(s)	 Schedule 3.18(a) to the Credit Agreement is hereby replaced with Schedule 3.18(a) attached hereto.

  

	 	(t)	 A new Exhibit J is added to the Credit Agreement in the form attached hereto and “Exhibit J Alkali
Group Distribution Policy” is hereto added to the Table of Contents under “Exhibits”. 

 SECTION
3.    Amendments to Guarantee and Collateral Agreement. As of the Ninth Amendment Effective Date, the Guarantee and Collateral Agreement is amended as follows: 

 

	 	(a)	 Section 1.01(b) of the Guarantee and Collateral Agreement is hereby amended by amending and restating the
definition of “Pledged Securities” as follows: 

 ““Pledged Securities” shall mean:
(i) the equity interests described or referred to in Schedule 2 hereto and any other equity interests now owned or hereafter acquired; and (ii) (a) the certificates or instruments, if any, representing such equity interests, (b) all
dividends (cash, stock or otherwise), cash, instruments, rights to subscribe, purchase or sell and all other rights and property from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all of such
equity interests, (c) all replacements, additions to and substitutions for any of the property referred to in this definition, including claims against third parties, (d) the proceeds, interest, profits and other income of or on any of the
property referred to in this definition and (e) all books and records relating to any of the property referred to in this definition.” 

  
 8 

	 	(b)	 Schedule 2 to the Guarantee and Collateral Agreement is hereby replaced with Schedule 2 attached
hereto. Schedule 4 to the Guarantee and Collateral Agreement is hereby replaced with Schedule 4 attached hereto. 

SECTION 4.    Conditions to Effectiveness. This Ninth Amendment shall not become effective until the date (the
“Ninth Amendment Effective Date”) on which each of the following conditions is satisfied (or waived in accordance with Section 9.02 of the Credit Agreement): 

 

	 	(a)	 The Administrative Agent shall have received from the Required Lenders and the Borrower executed counterparts
(in such number as may be requested by the Administrative Agent) of this Ninth Amendment. 

  

	 	(b)	 The Administrative Agent, the Arrangers and the Lenders shall have received all fees and other amounts due and
payable on or prior to the Ninth Amendment Effective Date, including to the extent invoiced, reimbursement or payment of all out of pocket expenses required to be reimbursed or paid by the Borrower under the Credit Agreement. 

 

	 	(c)	 Substantially simultaneously with the Ninth Amendment Effective Date, (i) the unit purchase agreement
governing the issuance and purchase of the Alkali Preferred Units (as defined in Section 2(a) above), in form and substance reasonably satisfactory to the Administrative Agent, shall be in full force and effect, (ii) the initial Alkali
Preferred Units shall have been issued in accordance with such unit purchase agreement, and (iii) the Administrative Agent shall have received an officer’s certificate from a Responsible Officer of the Borrower certifying as to the
foregoing and attaching the executed unit purchase agreement. 

  

	 	(d)	 After giving effect to the Ninth Amendment, (i) no Default or Event of Default shall have occurred and be
continuing and (ii) the Borrower shall be in compliance on a Pro Forma Basis with Section 6.14 of the Credit Agreement. 

  

	 	(e)	 The Administrative Agent shall have received such other documents as the Administrative Agent or special
counsel to the Administrative Agent may reasonably request. 

 The Administrative Agent shall notify the Borrower and the
Lenders of the Ninth Amendment Effective Date, and such notice shall be conclusive and binding. 
 SECTION
5.    Miscellaneous. 
 (a)    Confirmation. The provisions of the Loan Documents, as
amended by this Ninth Amendment, shall remain in full force and effect in accordance with their terms following the effectiveness of this Ninth Amendment. The execution, delivery and effectiveness of this Ninth Amendment shall not, except as
expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Administrative Agent under any of the Loan Documents, nor, except as expressly provided herein, constitute a waiver or amendment of any provision of
any of the Loan Documents. 

  
 9 

 (b)    Ratification and Affirmation; Representations and
Warranties. Each of the undersigned does hereby adopt, ratify, and confirm the Credit Agreement and the other Loan Documents, as amended hereby, and its obligations thereunder. The Borrower hereby (i) acknowledges, renews and extends its
continued liability under each Loan Document to which it is a party and agrees that each Loan Document to which it is a party remains in full force and effect, except as expressly amended hereby, notwithstanding the amendments contained herein,
(ii) confirms and ratifies all of its obligations under the Loan Documents to which it is a party, including its obligations and the Liens granted by it under the Security Documents to which it is a party, (iii) confirms that all
references in such Security Documents to the “Credit Agreement” (or words of similar import) refer to the Credit Agreement as amended and supplemented hereby without impairing any such obligations or Liens in any respect and all references
in the Loan Documents to the “Guarantee and Collateral Agreement” (or words of similar import) refer to the Guarantee and Collateral Agreement as amended and supplemented hereby without impairing such obligations or Liens in any respect
and (iv) represents and warrants to the Lenders that: (A) as of the date hereof, after giving effect to the terms of this Ninth Amendment, all of the representations and warranties contained in each Loan Document to which it is a party are
true and correct in all material respects (except that any such representations and warranties that are modified by materiality shall be true and correct in all respects), except to the extent any such representations and warranties are expressly
limited to an earlier date, in which case, such representations and warranties shall continue to be true and correct in all material respects as of such specified earlier date (except that any such representations and warranties that are modified by
materiality shall be true and correct in all respects as of such specified earlier date); and (B) as of the date hereof, after giving effect to this Ninth Amendment, no Default has occurred and is continuing. 

(c)    Loan Document. This Ninth Amendment and each agreement, instrument, certificate or document executed by the
Borrower or any other Borrower Party or any of its or their respective officers in connection therewith are “Loan Documents” as defined and described in the Credit Agreement and all of the terms and provisions of the Loan Documents
relating to other Loan Documents shall apply hereto and thereto. 
 (d)    Counterparts. This Ninth Amendment may
be executed by one or more of the parties hereto in any number of separate counterparts, and all of such counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of this Ninth Amendment by facsimile or other
electronic transmission shall be effective as delivery of a manually executed counterpart hereof. 
 (e)    NO ORAL
AGREEMENT. THIS NINTH AMENDMENT, THE CREDIT AGREEMENT AND THE OTHER LOAN DOCUMENTS EXECUTED IN CONNECTION HEREWITH AND THEREWITH REPRESENT THE FINAL AGREEMENT AMONG THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS,
OR UNWRITTEN ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO SUBSEQUENT ORAL AGREEMENTS BETWEEN THE PARTIES. 

  
 10 

 (f)    GOVERNING LAW. THIS NINTH AMENDMENT (INCLUDING, BUT NOT
LIMITED TO, THE VALIDITY AND ENFORCEABILITY HEREOF) SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 

(g)    THE PROVISIONS OF SECTION 9.09(B) AND (C) AND SECTION 9.10 OF THE CREDIT AGREEMENT SHALL APPLY, MUTATIS
MUTANDIS, TO THIS NINTH AMENDMENT. 
 [Remainder of page intentionally left blank] 

  
 11 

 IN WITNESS WHEREOF, the parties hereto have caused this Ninth Amendment to be duly executed
and delivered as of the date first written above. 
  

			
	BORROWER:
	
	GENESIS ENERGY, L.P.,
	
	By: GENESIS ENERGY, LLC, its general partner

 
			
		
	By:	 	 /s/ Robert V. Deere

	Name: Robert V. Deere
	Title: Chief Financial Officer

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
			
	GRANTORS:
	
	GENESIS CRUDE OIL, L.P.
	GENESIS PIPELINE TEXAS, L.P.
	GENESIS PIPELINE USA, L.P.
	GENESIS SYNGAS INVESTMENTS, L.P.
		
	By:	 	GENESIS ENERGY, LLC, 
its general partner

 
			
		
	By:	 	 /s/ Robert V. Deere

	Name: Robert V. Deere
	Title: Chief Financial Officer
	
	GEL CHOPS I, L.P.
	GEL CHOPS II, L.P.

 
			
		
	By:	 	GEL CHOPS GP, LLC, 
its general partner

 
			
		
	By:	 	 /s/ Robert V. Deere

	Name: Robert V. Deere
	Title: Chief Financial Officer and Treasurer
	
	CAMERON HIGHWAY PIPELINE I, L.P.

 
			
		
	By:	 	Cameron Highway Pipeline GP, L.L.C., its general partner

 
			
		
	By:	 	 /s/ Robert V. Deere

	Name: Robert V. Deere
	Title: Chief Financial Officer and Treasurer

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

					
		 		 	AP MARINE, LLC
		 		 	BR PORT SERVICES, LLC
		 		 	CAMERON HIGHWAY OIL PIPELINE COMPANY, LLC
		 		 	CAMERON HIGHWAY PIPELINE GP, L.L.C.
		 		 	CASPER EXPRESS PIPELINE, LLC
		 		 	DAVISON PETROLEUM SUPPLY, LLC
		 		 	DAVISON TRANSPORTATION SERVICES, INC.
		 		 	DAVISON TRANSPORTATION SERVICES, LLC
		 		 	DEEPWATER GATEWAY, L.L.C.
		 		 	FLEXTREND DEVELOPMENT COMPANY, L.L.C.
		 		 	GEL CHOPS GP, LLC
		 		 	GEL DEEPWATER, LLC
		 		 	GEL IHUB, LLC
		 		 	GEL LOUISIANA FUELS, LLC
		 		 	GEL ODYSSEY, LLC
		 		 	GEL OFFSHORE PIPELINE, LLC
		 		 	 GEL OFFSHORE, LLC
 GEL PALOMA,
LLC
 GEL PIPELINE OFFSHORE, LLC

		 		 	GEL POSEIDON, LLC
		 		 	GEL SEKCO, LLC
		 		 	GEL TEX MARKETING, LLC
		 		 	GEL TEXAS PIPELINE, LLC
		 		 	GEL WYOMING, LLC
		 		 	GENESIS BR, LLC
		 		 	GENESIS CHOPS I, LLC
		 		 	GENESIS CHOPS II, LLC
		 		 	GENESIS DAVISON, LLC
		 		 	GENESIS DEEPWATER HOLDINGS, LLC
		 		 	GENESIS ENERGY FINANCE CORPORATION
		 		 	GENESIS ENERGY, LLC
		 		 	GENESIS FREE STATE HOLDINGS, LLC
		 		 	GENESIS GTM OFFSHORE OPERATING COMPANY, LLC
		 		 	GENESIS IHUB HOLDINGS, LLC
		 		 	GENESIS MARINE, LLC
		 		 	GENESIS NEJD HOLDINGS, LLC
		 		 	GENESIS ODYSSEY, LLC
		 		 	GENESIS OFFSHORE HOLDINGS, LLC
		 		 	GENESIS OFFSHORE, LLC
		 		 	GENESIS PIPELINE ALABAMA, LLC

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

					
		 		 	GENESIS POSEIDON HOLDINGS, LLC
		 		 	GENESIS POSEIDON, LLC
		 		 	GENESIS RAIL SERVICES, LLC
		 		 	GENESIS SAILFISH HOLDINGS, LLC
		 		 	GENESIS SEKCO, LLC
		 		 	GENESIS SMR HOLDINGS, LLC
		 		 	 GENESIS TEXAS CITY TERMINAL, LLC

GENESIS WASATCH ADDITIVES, INC.

		 		 	HIGH ISLAND OFFSHORE SYSTEM, L.L.C.
		 		 	MANTA RAY GATHERING COMPANY, L.L.C.
		 		 	MATAGORDA OFFSHORE, LLC
		 		 	MILAM SERVICES, INC.
		 		 	POSEIDON PIPELINE COMPANY, L.L.C.
		 		 	RED RIVER TERMINALS, L.L.C.
		 		 	SAILFISH PIPELINE COMPANY, L.L.C.
		 		 	SEAHAWK SHORELINE SYSTEM, LLC
		 		 	SOUTHEAST KEATHLEY CANYON PIPELINE COMPANY, L.L.C.
		 		 	TBP2, LLC
		 		 	TDC SERVICES, LLC
		 		 	TDC, L.L.C.
		 		 	TEXAS CITY CRUDE OIL TERMINAL, LLC
		 		 	THUNDER BASIN HOLDINGS, LLC
		 		 	THUNDER BASIN PIPELINE, LLC

  

			
	By:	 	 /s/ Robert V. Deere

	Name: Robert V. Deere
	Title: Chief Financial Officer and Treasurer

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
			
	 WELLS FARGO BANK, NATIONAL ASSOCIATION,

as Administrative Agent, Issuing Bank and a Lender

 
			
		
	By:	 	 /s/ Andrew Ostrov

	Name: Andrew Ostrov
	Title:   Director

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
			
	 BMO HARRIS FINANCING, INC.,

as a Lender

 
			
		
	By:	 	 /s/ Kevin Utsey

	Name: Kevin Utsey
	Title:   Managing Director

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
			
	 DEUTSCHE BANK AG – NEW YORK BRANCH,

as a Lender

 
			
		
	By:	 	 /s/ Shai Bandner

	Name: Shai Bandner
	Title:   Director
		
	By:	 	 /s/ My Nguyen

	Name: My Nguyen
	Title:   Analyst

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
			
	ABN AMRO CAPITAL USA, LLC,
as a Lender
		
	By:	 	 /s/ Brody Summerall

	Name: Brody Summerall
	Title:   Vice President
		
	By:	 	 /s/ Darrell Holley

	Name: Darrell Holley
	Title:   Managing Director

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
			
	BNP PARIBAS, 
as a Lender
		
	By:	 	 /s/ Mark Renaud

	Name: Mark Renaud
	Title:   Managing Director
		
	By:	 	 /s/ Claudia Zarate

	Name: Claudia Zarate
	Title:   Managing Director

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
			
	CAPITAL ONE, NATIONAL ASSOCIATION, 
as a Lender
		
	By:	 	 /s/ Christopher Kuna

	Name: Christopher Kuna
	Title:   Director

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
			
	THE BANK OF NOVA SCOTIA, HOUSTON BRANCH, 
as a Lender
		
	By:	 	 /s/ Joe Lattanzi

	Name: Joe Lattanzi
	Title:   Managing Director

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
	
	SUMITOMO MITSUI BANKING CORPORATION, 
as a Lender
	
	By: /s/ Michael Maguire                               
                               
	Name: Michael Maguire
	Title:   Managing Director

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
	
	BANK OF AMERICA, N.A., 
as a Lender
	
	By: /s/ Pace Doherty                                
                                     
	Name: Pace Doherty
	Title:   Vice President

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

			
	CITIBANK N.A., 
as a Lender
		
	By:	 	 /s/ Michael Zeller

	Name: Michael Zeller
	Title:   Vice President

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
			
	ROYAL BANK OF CANADA, 
as a Lender
		
	By:	 	 /s/ Jason S. York

	Name: Jason S. York
	Title:   Authorized Signatory

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
			
	BBVA USA, 
as a Lender
		
	By:	 	 /s/ Mark H. Wolf

	Name: Mark H. Wolf
	Title:   Senior Vice President

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

			
	FIFTH THIRD BANK, 
as a Lender
		
	By:	 	 /s/ Jonathan H Lee

	Name: Jonathan H Lee
	Title:   Director

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
	
	 REGIONS BANK,
 as a Lender

	
	By: /s/ David Valentine                                
                                
	Name: David Valentine
	Title:   Managing Director

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
	
	 DNB CAPITAL LLC,
 as a
Lender

	
	By: /s/ Kelton Glasscock                               
                               
	Name: Kelton Glasscock
	Title:   Senior Vice President
	
	By: /s/ James
Grubb                                        
                             
	Name: James Grubb
	Title:   First Vice President

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
	
	 CADENCE BANK, N.A., 
 as a
Lender

	
	By: /s/ William W. Brown                               
                             
	Name: William W. Brown
	Title:   Executive Vice President

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
	
	 ZIONS BANCORPORATION, N.A. dba
 AMEGY
BANK,
 as a Lender

	
	By: /s/ Sam Trail                                 
                                         

	Name: Sam Trail
	Title:   Senior Vice President

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
	
	 TRUSTMARK NATIONAL BANK,
 as a
Lender

	
	By: /s/ Jeff Deutsch                                
                                      
	Name: Jeff Deutsch
	Title:   Senior Vice President

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
	
	 COMERICA BANK, 

 as a
Lender

	
	By: /s/ Britney P. Geidel                              
                                
	Name: Britney P. Geidel
	Title:   Portfolio Manager, AVP

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement] 

 
	
	 BOKF, NA dba BANK OF TEXAS, 

 as a
Lender

	
	By: /s/ Mari Salazar                                
                                      
	Name: Mari Salazar
	Title:   Senior Vice President

 [Signature Page – Ninth Amendment to Fourth Amended and 

Restated Credit Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]